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Abstract
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an inflammatory
autoimmune peripheral nerve disorder. CIDP is associated with demyelination, slow
motor nerve-conduction velocity, and distal muscle weakness. CIDP is under-recognized
due to its heterogeneous presentation and the limitations of clinical diagnostic criteria.
Using a combination of electrophysiology and muscle imaging techniques the four
studies outlined in this thesis systemically investigate the impacts of this demyelinating
disease on motor nerves and their innervated muscles.
The first two studies examine the neuronal consequences of demyelination caused by
CIDP and the following two studies investigate how skeletal muscle is affected by these
neuronal complications. Specifically, the purpose of study 1 was to investigate whether
patients with CIDP demonstrate motor unit loss, and to determine the neuromuscular
transmission stability of motor units. Results showed patients with CIDP have reduced
motor unit number estimates (MUNEs), in addition to motor unit instability and
transmission blocking in the tibialis anterior (TA) muscle. The purpose of study 2 was to
investigate modifications to motor unit discharge characteristics of affected motor units.
The results indicate CIDP leads to axonal or neuromuscular block and abnormally high
motor unit firing rates of early recruited motor units as a compensatory mechanism to
mitigate the frank neuronal loss in the TA.
The purpose of studies 3 and 4 was to assess the consequences of peripheral axon loss
and motor unit instability on muscle quality and quantity in patients with CIDP. It is
critical to investigate whether these neuronal changes precipitate uniform alterations in
ii

musculature. Study 3 showed that patients with CIDP have less overall muscle mass and
more non-contractile tissue infiltration in the TA of the anterior leg compartment. Study
4, demonstrated that muscles in the posterior leg compartment, that differ functionally
from the TA and are innervated by a different portion of the sciatic nerve undergo similar
morphological changes to the TA. In combination, these neuronal deficits and skeletal
muscle structural abnormalities likely lead to muscle weakness and functional
impairment seen in patients with CIDP. Together these studies form a foundational
understanding of how CIDP impacts both nervous and muscle tissue at a systems level.

Keywords
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); peripheral nervous
system; muscle; human; weakness; motor unit; electromyography (EMG); magnetic
resonance imaging (MRI).
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Summary for Lay Audience
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an ultra rare immune
mediated neurological disorder in which there is inflammation of peripheral nerves and
destruction of the fatty protective covering (myelin sheath) surrounding the nerves, which
affects how fast the nerve signals are transmitted to their attached muscles. This causes
weakness, paralysis and/or impairment in motor function, especially of the arms and legs.
Sensory disturbance may also be present. The motor and sensory impairments usually
affect both sides of the body (symmetrical), and the degree of severity and the course of
disease may vary greatly among individuals. Tests that can be of diagnostic help include
nerve conduction testing and electromyography that demonstrate slow nerve conduction
velocities, lumbar puncture with evidence of elevated spinal fluid protein and magnetic
resonance imaging (MRI) of the nerve roots looking for enlargement and signs of
inflammation. Despite this there is a lack of awareness and knowledge surrounding a
specific cause and disease mechanism in CIDP making diagnosing the disease very
difficult.
To date no studies have systematically investigated the neuronal and musculoskeletal
consequences of this nerve disease. Therefore, it is critical to study the function of the
peripheral nerves in this inflammatory disorder as well as their connection to skeletal
muscle. In this work I investigated two main phenomenon related to CIDP. The first two
studies of this thesis quantify the loss of motor nerves as well the health of the remaining
motor nerves in response to the demyelinating process. The two subsequent studies
investigate the repercussions of motor unit loss on the amount and quality of the muscles
attached to these unhealthy nerves. The findings from this work demonstrate that patients
iv

with CIDP not only have fewer motor units; the remaining motor units are very
unhealthy. This reduction of motor units in combination with the poor connection these
motor units have with their attached muscle leads to major losses in the amount and
quality of muscle tissue. Overall, this work provides compelling evidence for the
reasoning behind the functional strength decrements patients exhibit with CIDP.
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Chapter 1

1

General Introduction

Beginning in the early eighteenth century, neurobiologists attempted to discover a link
between electricity and how nerves function. Luigi Galvani took the first steps in laying
the foundation of modern electrophysiology by demonstrating the presence of electricity
in dissected frogs1. Julius Bernstein and Emil du Bois-Reymond, in 1843 were the first to
accurately describe a phenomenon called the action potential

2,3

. Throughout the next

half-century, others went on to show that nerve and muscle tissues generate electrical
transients that accompany this nervous excitation. Although the field of neuroscience has
progressed

immensely

our

comprehension

of

numerous

components

within

neuromuscular physiology continue to elude our understanding. Specific amongst these,
are inquiries concerning the influences disease has on nerves and what consequences
these nerve abnormalities have on connected muscle. A more comprehensive
appreciation regarding neuromuscular disease processes may ultimately lead to early
diagnosis or enhanced treatment options allowing individuals with nerve diseases the
opportunity to mitigate the devastating consequences of muscle atrophy.

1.1 The Neuromuscular System Anatomy/Physiology and the
Motor Unit in Humans
1.1.1

Neuromuscular System

The neuromuscular system, composed of nerves and muscles, provides humans with the
means to coordinate movement and is essential in controlling posture and gait.
Specifically, the neuromuscular system is responsible for transmitting signals from the
central nervous system (brain and spinal cord) to skeletal muscle and is comprised of a
1

circuit of motor neurons and skeletal muscles. Electrical impulses elicited in the motor
neuron’s cell body propagate along the motor axon and result in the release of
the neurotransmitter, acetylcholine, from the motor nerve terminal at a synaptic
connection, termed the neuromuscular junction. The neurotransmitter molecules of
acetylcholine diffuse across this neuromuscular junction and bind acetylcholine receptors
on the muscle fiber. The binding results in the opening of ion channels within the muscle
fiber, thus altering the muscle membrane potential. This muscle membrane depolarization
then triggers a release of internal calcium ions that leads to a cascade of events resulting
in skeletal muscle contraction 4. The neuromuscular system is substantially more complex
than outlined above and many questions remain unanswered. Investigation of
modifications to nerves and muscles due to disease (e.g. demyelinating polyneuropathies)
can provide useful insight into basic neuromuscular pathophysiology and the mechanisms
responsible for the functional limitations seen in patients. Of most interest to the study of
neuromuscular diseases and the focus of this dissertation is this vital connection between
the nerves and their accompanied muscle.

1.1.2

The Motor Unit

A single motor unit is composed of an individual motor axon called an α-motor neuron,
and all skeletal muscle fibres innervated by this distinct axon. In humans there are two
major types of motor units: type I and type II. Fundamentally, small motor units have
smaller axon diameters, fewer fibers that make up the complete unit, and are more
resistant to fatigue. These motor nerves innervate slower muscle fibers and are referred to
as type I motor units. Large motor nerves innervate larger, faster muscle fibers that are
less resistant to fatigue and are referred to as type II motor units. The number of muscle

2

fibers in a specific motor unit is directly correlated to the size of the motor neuron for that
5

unit . The size of a motor unit is defined by the number of muscle fibres it innervates and
varies significantly in different motor units from dozens of muscle fibres per unit to
thousands of muscle fibres per unit (Figure 1.1) 6.
A small motor unit’s cell body located in the ventral horn of the spinal cord has a low
excitation threshold to cause an action potential. Therefore, less excitation input is
required for small cell bodied neurons and a motor unit that has a smaller cell body also
has a smaller nerve fiber that innervate fewer muscle fibers when activated. For this
reason specifically, smaller, type I motor units are more easily discharged and are also
more impervious to fatigue. Conversely, larger type II motor units can activate hundreds
of muscle fibers collectively with a single action potential from a motor neuron 7. Due to
their direct relationship, muscle fibers are commonly referred to by their motor unit type.

Spinal cord

Type I
MU 1

Type II
MU 2 Neuromuscular
junc on

Nerve
Motor neuron
cell body
Motor neuron
axon

Muscle

Muscle fibers
Tendon

Figure 1.1 The motor unit

3

Two separate motor units are depicted (Type I and Type II). α-motor neuron cell bodies are located in the
ventral horn of the spinal cord. The axon exits the ventral horn into the periphery and synapses with their
respective muscle fibers at the neuromuscular junction. Each motor unit is composed of an individual αmotor neuron and all attached muscles fibers. Adapted from: Ko 2001 4

Skeletal muscles composed of smaller motor units are capable of finer, more accurate
control. This would be advantageous for small muscles required for refined movements
such as muscles in the hand. Alternatively, motor nerves innervate larger muscles
responsible for gross or powerful movements

8,9

. The force exerted by a muscle during a

voluntary contraction depends on the number of motor units that are activated and the
rates at which these motor units discharge action potentials. These two properties of
voluntary contractions are known as recruitment and rate coding. At low levels of
voluntarily muscle contraction, smaller type I motor units are generally recruited prior to
6,8

larger type II motor units, a concept referred to as the Henneman size principle

. The

Henneman size principle states that the recruitment of motor units within a muscle
proceeds from small motor units to large motor units. Small motor units have low
thresholds of activation and are recruited first. Larger motor units with higher thresholds
10

of activation follow are recruited later .
In contrast, rate coding refers to the modulation of motor unit action potentials whereby
the force of a muscle fibre is modified by increasing or decreasing the frequency at which
motor neurons discharge to their coupled muscle fibres

11

. Experimental evidence

suggests that recruitment is the more significant factor at low forces, whereas rate coding
is more responsible for changes in muscle force at intermediate and high forces 10.

4

1.2
Schwann Cells, the Myelin Sheath and Saltatory
Conduction
Schwann cells are derived from neural crest cells, and are of two types: myelinating or
non-myelinating Schwann cells. Myelinating Schwann cells form a tightly wrapped lipid
bilayer that surrounds the motor axon composed of specialized protein constituents and is
structurally and electrically critical for the propagation of nerve impulses and axonal
maintenance 12. Schwann cells also play a pivotal role in maintaining the nervous system
and are vital in motor axon regeneration. The presence of myelin along the length of the
α-motor neuron is essential to maintain conduction velocity; its loss or damage can lead
to significantly slower conduction or conduction block. In certain peripheral
neuropathies, electrical propagation blockade may be the preliminary event in the cascade
of events leading to the loss of Schwann cells in a process called demyelination 14. Along
the length of an α-motor neuron the myelin sheath formed by Schwann cells is
interrupted at regular intervals (nodes of Ranvier) where the axon membrane containing
voltage gated sodium channels is exposed to the extracellular environment

14

. The

propagation of action potentials along the length of motor axons relies on the
collaborative action of these membrane-spanning selectively permeable ion channels

15

.

Specifically, myelinated α-motor neurons feature an extremely organized distribution of
voltage-gated ion channels, with a characteristic clustering of Na+ channels at the nodes
of Ranvier. Saltatory conduction in myelinated axons refers to the rapid propagation of
the electrical waveform from each node to the next. In this process myelinated axons only
permit action potentials to transmit at the unmyelinated nodes of Ranvier. This ionic
restriction allows saltatory conduction to propagate an action potential along the motor
axon at rates significantly higher than would be achievable in the absence of myelination.
5

As sodium rushes into the node it creates an electrical diffusion gradient, which drives
the ions contained within the axon’s cytoplasm

16

.

This rapid conduction of ionic

signaling reaches the next node and generates another action potential, thus revitalizing
the electrical signal (Figure 1.2). In this manner, saltatory conduction allows electrical
nerve signals to be propagated along the axon length almost instantaneously without any
degradation of the signal

16,17,18

. Focal disruption (segmental demyelination) of

the myelin sheath can lead to failure of impulse conduction in the denuded axon segments
(termed conduction block) in part because of a paucity of voltage-gated sodium
ion channels between the nodes of Ranvier. Conduction block is a feature of many
demyelinating conditions.

6

Figure 1.2 Saltatory conduction
Schematic depicts an action potential propagation down the length of an axon by method of saltatory
conduction. As sodium rushes into the node it creates an electrical force that pushes on positively charged
ions already inside the axon. This rapid conduction of electrical signal reaches the next node and creates
another action potential refreshing the action potential. Saltatory conduction allows electrical nerve signals
to be propagated at high rates, long distances. Adapted from: Rash et al 2016 18

1.3
Chronic Inflammatory Demyelinating Polyneuropathy
(CIDP)
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological
disorder characterized by inflammation of nerve roots and peripheral nerves and
destruction of the myelinating Schwann cell covering the axon. The reported prevalence

7

of CIDP ranges from 0.7 to 10.3 cases per 100,000 people

19

. CIDP primarily affects

adults and the incidence rises with advancing age. Although not well established there
seems to be a male predominance and an age of onset is not known. No specific
predisposing factors for CIDP have been identified

20

. There is heterogeneity in clinical

phenotypes in CIDP, and it may not be a discrete disease entity but rather a spectrum of
discrete albeit related conditions. Commonly reported phenotypes of CIDP include motor
and sensory nerve dysfunction, with motor deficits reported in up to 94% of patients and
sensory deficits in up to 89% 21. The prognosis of CIDP is variable and is reminiscent of
multiple sclerosis in its heterogeneity. Some patients (20-65%)

22

follow a relapsing

remitting course, others a more progressive course. Over time, most patients without
associated confounding conditions respond to treatment.

1.3.1

Clinical Diagnosis

The diagnosis of CIDP depends on a combination of clinical and electrophysiological
criteria. The European Federation of Neurological Societies (EFNS)/Peripheral Nerve
Society (PNS) guidelines were developed for clinical and research use

22

. The EFNS

criteria combine clinical features in combination with electrophysiological evidence to
define CIDP. In addition to the guidelines, supportive criteria include: elevated
cerebrospinal fluid (CSF) protein, gadolinium enhancement of nerve roots or plexus on
magnetic resonance imaging (MRI) in addition abnormal nerve biopsy findings provide
complementary diagnostic evidence. In abnormal nerve biopsies thinly myelinated large
axons are most frequently observed. Importantly, electrodiagnostic evidence of peripheral
nerve demyelination specifically in motor nerves is required for diagnosis. Segmental
demyelination and remyelination are also hallmarks of CIDP and repetitively over time

8

lead to onion bulb formations by proliferation of Schwann cell processes covering motor
axons.
For a definitive diagnosis of CIDP the following electrophysiological indications must be
identified in at least two nerves: latency prolongation, reduction of motor conduction
velocity, prolongation of F-wave latency reduced compound muscle action potentials
(CMAPs), and partial motor conduction block 22. The features of CMAPs and conduction
block and how they pertain to CIDP will be discussed in greater detail below. Clinical
patient workup includes muscle strength evaluation (MRC 0-5 scale), Overall
Neuropathy Limitations Scale (ONLS) score, ataxia score and 10‐m walk test. Other tests
and functional scales are used depending on symptoms (grip test, nine‐hole peg test, and
Inflammatory Neuropathy Cause and Treatment Sensory Sum Score). Although, other
diagnostic guideline criteria have been suggested the EFNS/PNS criteria have
demonstrated sensitivity and specificity for CIDP diagnosis and are currently the most
commonly used 23, 24.

1.3.2

Differential Diagnosis

CIDP is distinguished from acute inflammatory demyelinating polyradiculoneuropathy
(AIDP) in that it is a monophasic disorder with nerve damage due to an immune response
to a single (infectious) event as well as treatment responsiveness. Unlike AIDP, CIDP
typically has a more indolent course and published criteria for CIDP recognize time to
greatest weakness of longer than 8 weeks as the defining feature that differentiates CIDP
from AIDP

19

. CIDP disease presentation is usually classified into three subtypes. A

progressive from in that the disease continues to worsen over time regardless of

9

immediacy and type of treatment. A recurrent form that has episodes of symptoms that
starts and stops over time and lastly a monophasic form. The monophasic form is defined
as a single bout of the disease that has a duration of one to three years, but does not ever
recur

22

. CIDP is often misdiagnosed as Guillain-Barré Syndrome (GBS), the most

common form of AIDP, and for this reason finding more robust diagnostic criteria is
critical to proper disease diagnosis and prognosis.

1.3.3

Pathology of CIDP

The principal theory of CIDP pathogenesis is that cell-mediated and humoral
mechanisms act synergistically to cause damage to the peripheral nerves. Several lines of
evidence support the conclusion that CIDP is an autoimmune disease mediated by
cellular immunity against yet to be undefined Schwann cell myelin protein antigens.
Some patients have reported infections prior to onset of neurological symptoms, however
no specific trigger for the autoimmune response has been identified and no infectious
agent has been consistently linked with initiation of CIDP

25

. There have been some

recent advances in the area of the pathophysiological significance of autoantibodies
directed specifically towards the nodal regions of peripheral axons in patients with CIDP.
It has become clear that the anatomical and the molecular complexity of the node of
Ranvier affects the ability of antibodies to bind and is the likely pathogenicity of the
immune response in CIDP. In a normal, healthy axon, the myelin sheath wraps around
the axon and ion channels are clustered in the unmyelinated nodes of Ranvier. This
enables Saltatory conduction down the length of the axon. In CIDP, there is systemic
infiltration of T-cells, B-cells, plasma cells, and macrophages, which lead to a cascade of
events including the release of pro-inflammatory cytokines and antibodies, which are

10

destructive to both the myelin and axons (Figure 1.3).

Axonal damage and

neurodegeneration occur simultaneously with focal inflammation. There is ongoing
demyelination due to antibodies against myelin antigens. Demyelination leads to the
redistribution of ion channels, which impairs conduction along the axon. It is a
combination of these events, rather than one in particular that contributes to
neurodegeneration and axonal damage in CIDP 25,26.

1

2

3

Figure 1.3 Axonal damage in CIDP
(1) Depiction of a healthy axon, the myelin sheath (blue) wraps around the axon and Na ion channels
(orange) are clustered in the unmyelinated nodes of Ranvier. This enables saltatory conduction down the
length of the axon. (2) Systemic infiltration of T-cells, B-cells, (purple cells) plasma cells (green cells), and
macrophages (aqua cells) leading to a release of pro-inflammatory cytokines and antibodies (black and blue
Y) that are destructive to both myelin and axons. (3) Ongoing demyelination due to antibodies against
myelin antigens leads to the redistribution of ion channels that impairs action potential conduction along
the axon. Adapted from: Salapa et al 2017 27

A combination of MRI, ultrasound and autopsy studies have established that the
inflammatory lesions in CIDP arise predominantly in the spinal roots, proximal nerve

11

trunks and major plexuses and are often spread throughout smaller peripheral nerves 25,26.
However, due to the inaccessibility of proximal nerves and nerve roots for diagnostics,
most clinical nerve biopsies are obtained from the sural nerve. Although the sural nerve is
peripheral and located furthest from the most prominent inflammatory activity in the
proximal nerve roots, pathophysiological changes in sural nerve biopsies reflect the broad
spectrum of changes seen in CIDP. Pathological observations in sural nerve biopsies
include demyelination, formation of onion bulbs, oedema, perivascular or endoneurial
macrophage inflammatory infiltrates and T cells and axonal degeneration

25,26

. In blood

and CSF of patients with CIDP studies have shown changes in the function and
abundance of T cell subsets, altered expression of cytokines and other inflammatory
mediators

28,29,30

. An animal model of CIDP called experimental autoimmune neuritis

(EAN), demonstrates similar pathological changes to those observed in humans. This
animal model of CIDP is induced in susceptible strains of rodents or rabbits by
immunization with specific myelin proteins and is the result of an autoimmune attack on
peripheral nerves mediated by macrophages and T-cells 31.

1.3.4

Treatment of CIDP

There are three conventional treatments prescribed for CIDP. Glucocorticoid drugs such
as prednisone have proven effective in large patient trials. In many cases, individuals
with CIDP may respond to glucocorticoid treatment alone

32

. However, individuals

requiring high doses of glucocorticoid drugs may experience side effects that deter longterm therapy. Steroid drugs only act to reduce the inflammation and their long-term use
in patients with CIDP has not been well-established

32

. Intravenous immunoglobulin

(IVIG) has been also been proven to be effective and is often used as a treatment for
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CIDP either alone or concurrently with glucocorticoids

33,34

. IVIG acts to suppress the

proliferation of antigen-specific T cells, which diminishes the autoimmune insult on
peripheral nerves. Lastly, plasma exchange (PE) has been shown in clinical trials to
benefit individuals with CIDP 33. The process of PE involves removing whole blood from
an individual with CIDP and red blood cells are subsequently separated from plasma. The
plasma is then replaced with healthy human plasma and the patient’s blood cells are
transfused back into the systemic circulation, thus removing only the plasma and its
constituents. Importantly, IVIG and PE are effective only for a few weeks and may
require chronic intermittent refresher treatments.

1.3.5

Functional Consequences of CIDP

Patients with CIDP can experience motor and or sensory disturbances and when
combined can exacerbate functional consequences of the disease. Briefly, most
individuals with CIDP experience some alterations of sensation causing sensory ataxia
(loss of coordination) and paresthesia. Some patients only have sensory symptoms and
signs but demonstrate typical abnormalities of nerve conduction and respond to
treatment. This is considered the sensory variant of CIDP. Other common more severe
systemic sensory symptoms include: chronic fatigue, pain, dysphagia, and diplopia.
Importantly, gait will be abnormal and proprioceptive responses to various environmental
sensory stimuli will be impaired. In cases of typical CIDP, motor decrements present
symmetrically in a length dependent fashion with chronically progressive, stepwise or
recurrent proximal and distal muscle weakness in all extremities. Although it is thought
that the degree of muscle atrophy in CIDP is generally mild given the general severity
and duration of weakness, some studies using computerized tomography (CT) have

13

shown patients to have muscle atrophy particularly in distal musculature

36

. Higher

prevalence of muscle atrophy is reported amongst patients with longer disease durations
or delayed treatment initiation. In patients with marked muscle atrophy, muscle weakness
and atrophy primary affect lower extremities, whereas in patients without marked muscle
atrophy, the upper and lower limbs are equally affected

37

. Studies also establish that

patient functional status (as determined by the MRS) are significantly worse in patients
with discernable but not quantified muscle atrophy

38

. Overall, many individuals with

CIDP are left with residual muscle weakness, tremors, fatigue, as well other symptoms
that can lead to diminished quality of life and long-term morbidity.

1.4
Motor Unit Number Estimations (MUNE) Using
Decomposition-based Quantitative Electromyography
(DQEMG)
Since the early days of neurophysiology research it has been recognized that the loss of
motor units has been a crucial physiological process fundamental in various
39

neuromuscular diseases

Consequently, it has been of great interest to develop

methodologies for in vivo quantification of functional motor units in a single muscle.
Motor unit number estimate (MUNE) was developed to quantify the number of motor
units in a specific muscle. Early MUNE techniques were developed to circumvent the
limitations associated with standard clinical electrophysiological techniques, which only
provided a qualitative physiological assessment of functional motor units. Since the
original establishment of MUNE, the technique has been vastly improved

39,40

. In recent

years, powerful digital signal processing capabilities have provided the impetus for
developing new automated and semi-automated techniques designed to estimate the
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number of functioning motor units in vivo

41

. MUNE is established upon the ratio

between a maximal compound muscle action potential (CMAP) that is divided by a mean
surface motor unit potential (SMUP)

42

. The CMAP signifies the absolute maximal

electrophysiological size of the complete motor unit population within a muscle. The
mean SMUP characterizes the absolute size of the average representative sample of a
single motor unit

34

. Currently no gold standard methodology exists regarding counting

human motor units or motor axons even with in vitro immunohistochemistry
preparations.
Decomposition-based quantitative electromyography (DQEMG) is the quantitative in
vivo assessment of motor unit action potentials from individual motor units and can
provide valuable information in assessing the integrity of human motor units 42. DQEMG
incorporates a combination of intramuscular electromyography (EMG) and surface EMG
to decompose complex EMG patterns into individual motor unit action potential trains
41,43

. This allows DQEMG software to deliver more detailed information for each motor

unit train such as: motor unit size, shape, stability and most importantly the DQEMG
software is used to acquire an estimate of the number of functioning motor units within a
single muscle 44,45. DQEMG uses two sources of EMG (micro and macro signals) to gain
insightful information regarding specific motor unit characteristics

45

. Micro signals are

gathered through intramuscular needle EMG electrodes. These micro EMG signals are
usually collected via concentric needle electrodes during sustained 30-second volitional
isometric contractions

44,45

. Originally this micro needle EMG signal, collected through

low to moderate level muscle contractions, consists of complex EMG interference
patterns from multiple simultaneously active motor units. DQEMG uses a series of
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algorithms to decompose this complex micro EMG pattern into constituent individual
motor unit action potential trains. Each action potential train belonging to a single motor
unit is classified based on shape and firing rate variability

43,44,45

. Macro (surface EMG)

signals are collected via surface electrodes, and provide EMG information regarding the
overall size and spatial distribution of active individual motor units. By using each
individual micro needle motor unit action potential train as a trigger for the macro signal,
the macro signal is temporally aligned with the decomposed micro needle signal. Time
locking of the macro EMG signal to the micro needle detected action potentials, allows
for the derivation of SMUPs, which resemble the corresponding size of individual motor
units within an active muscle and are used as the denominator in the MUNE calculation
40

.

Using DQEMG software to calculate a MUNE has been reported with high degrees of
intra- and inter-rater reliability 46,47,48,49. Numerous studies have shown that contraction
intensity has a discernible effect on DQEMG derived MUNE calculations

50

. Studies

executed in different muscles have found that with increasing contraction intensities
mean SMUP size increases, which inversely decreases the MUNE for that specific muscle
51

. One study concluded that a contraction intensity of 25% of maximum voluntary

contraction (MVC) in the tibials anterior (TA) muscle, recruits a representative sample of
low (type I) and high (type II) threshold motor units and thus provides the most
representative motor unit number estimation in the TA muscle

51,52

. Importantly,

DQEMG also conveys detailed electrophysiological data regarding the morphological
characteristics of individual needle detected motor unit action potentials

41,42

.

Morphological characteristics include: motor unit firing rates, motor unit firing rate
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variability, motor unit action potential size (area and amplitude), motor unit action
potential shape and complexity (turns, phases) and motor unit discharge stability (jitter,
jiggle, and % blocking).
Increases in motor unit action potential complexity as well increased action potential
amplitude are electrophysiological indications of enlarged, collaterally reinnervated
motor units, which have been associated with numerous neurological disease processes
49

. Motor unit action potential stability signifies the integrity of neuromuscular

transmission, either at the neuromuscular junction (NMJ) or within the muscle fibre itself.
This motor unit stability is examined through the detailed assessment of the variability in
shape of each consecutively detected action potentials. There are two key motor unit
stability properties associated with shape variability termed jitter and jiggle 52,53,54. Jitter
represents the variability in the time intervals between pairs of individual muscle action
potentials from a single motor unit, and jiggle refers to the overall variability in motor
unit action potential shape from one discharge to the next

55,56

(Figure 2.1). Abnormal

neuromuscular stability, specifically increased jitter and jiggle have been detected in
conditions that involve neuromuscular transmission interruptions and are indicative of
early axonal denervation

55,56

. Lastly DQEMG provides a measure of the percentage of

motor units that are blocked. Percent (%) blocking is a measure of unsuccessful motor
unit action potential transmissions in a muscle fibre or axon and is a clinically prominent
feature of many demyelinating diseases

56

. Most clinical diagnostic EMG studies are

performed at minimal submaximal contraction intensities, which severely limit clinical
needle EMG assessments to moderately few and entirely low threshold (type I) motor
units, which inherently biases the motor unit data obtained

56

. Fundamentally, DQEMG
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delivers an irreplaceable and appropriate paradigm in combination with needle detected
motor unit action potential examination and MUNE measures to gain a more
comprehensive understanding of the pathological changes to motor units that underlie
nerve dysfunction in CIDP.

1.5

Intramuscular Needle Electromyography

During voluntary contractions, the central nervous system regulates muscle force by
changing the number of motor units recruited. As discussed above additional force
regulation is achieved by varying the individual motor neuron firing rates. Once
maximum force has been established, no useful purpose is served by any further increase
in motor neuron discharge frequency. In recent years, the precise measurement of
individual motor-unit firing rates during voluntary contractions became possible using
tungsten micro- electrodes

57,58

. Tungsten microelectrodes provide a high signal-to-noise

ratio, allowing clear identification of single muscle fibre action potential trains even at
the highest forces. Briefly the tungsten micro electrode consists of a 5 cm long, 0.2-mm
diameter needle with an insulated tungsten shaft and a 10-15um exposed tip. For
successful recording of single muscle fibre action potentials with a high signal-to-noise
ratio, an electrode impedance greater than 100 Ω is generally required

59

. The tungsten

electrode is inserted through the skin until the tip is directly below the muscle surface. As
a subject volitionally contracts, the needle is further slowly and progressively advanced
(typically l-3 mm at each contraction) such as to record trains of potentials from as many
muscle fibres as possible (see Figure 3.1)

59

. The advantage of the tungsten technique

over using conventional recording electrodes and DQEMG, is the isolation of single-unit
firing rates during high-force contractions which is not possible with conventional
18

techniques since the potentials arising from single units are not clearly distinguished from
each other at forces exceeding 75-80% MVC 58,59,60. Numerous studies in neuromuscular
diseases such as Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) have
used this intramuscular tungsten technique to quantify motor unit firing rates resulting
from targeted axonal damage

61,62

. Results from the tibialis anterior muscle in patients

with ALS indicate that the physiological modulation of motor neuron firing rate is
decreased as well the variability of MU discharges tends to be greater in this disease 63.
Only a minutia of clinical data exists regarding motor unit firing rates in CIDP, most of
which only records from early recruited motor units and to date there have been no
systematic studies investigating motor unit firing behaviour in individuals with CIDP
especially at maximal firing rates.

1.6

Magnetic Resonance Imaging (MRI)

Magnetic resonance imaging (MRI) is a medical imaging technique used to form images
of the internal structures and anatomy. MRI works by using the magnetization properties
of the atomic nuclei. This imaging technique employs a uniformly powerful external
magnetic field, which aligns the protons that are normally randomly oriented within
water nuclei of the tissue under examination. This alignment called magnetization is than
perturbed or disrupted by introducing energy from an external Radio Frequency (RF) 64.
After being perturbed the atomic nuclei return to their resting alignment through a
relaxation processes, which emits RF energy that is measured for a specified period of
time. The signal from the internal structures contain location information and are sorted
in planes corresponding to intensity levels which appear as shades of gray in a matrix
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arrangement of pixels. The sequence or frequency of RF pulses applied and collected can
create different images.
Repetition Time (TR) is the amount of time between successive pulse sequences applied
to the same slice of tissue and Time to Echo (TE) is the time between the delivery of the
RF pulse and the receipt of the echo signal

64,65

. The different human tissue types can be

characterized by two different relaxation times T1 and T2. T1 or longitudinal relaxation
time is the time constant which determines the rate at which excited protons return to
equilibrium. This is a measure of the time taken for spinning protons to realign with the
external magnetic field. T2 or transverse relaxation time is the time constant, which
determines the rate the excited protons reach equilibrium or go out of phase coherence.
There has been a growing interest in MRI assessment of the peripheral nervous system in
dysimmune or autoimmune neuropathies, especially in patients with CIDP 66,67,68.
The first reported descriptions of nerve abnormalities, using conventional MRI was in the
1990s. Since then, higher strength and advanced MRI imaging sequencing techniques
have enabled a better discrimination of the peripheral nervous system and a better
characterization of nerve abnormalities. Typical MR findings in CIDP include
nerve enlargement, T2 signal increase and enhancement of nerve roots, especially in the
early stages of the disease when inflammation tends to be unmanaged

67,68

. Proximal

nerve involvement is typical at the onset of CIDP and becomes more prominent and
ubiquitous in the long-term. Imaging studies show nerve enlargement is positively
correlated with disease duration

67,68

. However, correlation of MRI features with clinical

disability seen in patients with CIDP, specifically functional losses of strength, are still
lacking. Most previous work involving the MRI assessment of CIDP were focused on
20

the spinal nerve roots and proximal nerve trunks, and there is a paucity of work
investigating the muscles that connect to these peripheral nerves. Importantly with the
advancement in imaging techniques the distal extremities can be imaged with smaller
surface coils reaching greater resolution. This allows direct and definitive visualization of
skeletal musculature affected by demyelinated peripheral nerves seen in patients with
CIDP. It is critical to investigate the degree of muscle atrophy associated with CIDP as
well to quantify the infiltration of non-contractile tissue to help elucidate reasoning
behind function muscle weakness in patients with CIDP.

1.7

Purposes and Hypotheses

The fundamental objective of the studies characterized within Chapters 2, 3, 4, and 5 was
to examine the pathophysiological effects of CIDP on the human neuromuscular system.
Previous investigations in CIDP have minimally explored the impacts of demyelination
on axonal function and none to date has focused on the fundamental consequential
changes to skeletal muscles innervated by chronically demyelinated nerves. In Chapter 2
the purpose was to determine if the loss of strength reported in patients with CIDP is
related to a loss of motor units. Furthermore, I wanted to assess motor unit functional
stability as quantified using DQEMG. It was hypothesized that patients with CIDP would
have fewer and less stable motor units compared to healthy controls, and decreased
MUNEs would be related to loss in strength observed in patients with CIDP.
The purpose of Chapter 3 was to investigate the specific motor unit firing patterns of
demyelinated and remodelled motor units. Commonly, clinical data are recorded from
small, low-threshold, early recruited motor units. However, it is not known how larger
demyelinated motor units that are recruited at higher contraction intensities are affected
21

by disease demyelination and inflammation. If patients with CIDP have disruptions to
motor unit firing patterns, that could further explain functional weakness. It was
hypothesized that motor unit firing rates would be depressed at all levels of voluntary
contractions in individuals with CIDP due to chronic peripheral nerve demyelination and
conduction block.
To date, the vast majority of studies investigating nerve dysfunction focus on evidence of
demyelination or nerve lesions detectable via imaging. Very few studies have focused on
the repercussions of CIDP on the quantity and quality in the associated musculature.
Therefore, the purpose of Chapter 4 was to determine how motor unit loss, instability and
blocking affect the tibialis anterior musculature of patients using a general anatomical
scan (T1) as well spin-echo (T2) MRI sequences. It was hypothesized that patients with
CIDP would feature a greater degree of tibialis anterior muscle atrophy as well larger
infiltrations of non-contractile tissue.
The purpose of Chapter 5 was to assess if nerves that supply the posterior leg muscles are
affected by the demyelinating process to the same degree as the nerves supplying the
anterior leg and if this leads to differences between compartments and muscles in overall
composition. It was hypothesized that patients with CIDP would have uniform alterations
both in the anterior and posterior musculature of the leg and proportions of noncontractile intramuscular tissue would be homogeneous in the two compartments.
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Chapter 2
1

Electrophysiological And Neuromuscular Stability Of
Persons With Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP)

2

2.1

Introduction

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a generalized
neuropathy of immunological origin. It is as a heterogeneous disease of symmetrical
muscle weakness, which includes sensory and motor deficits in both proximal and distal
limbs that progressively increases for >2 months 1. The condition is associated with
absent or diminished tendon reflexes, signs of demyelination, elevated cerebrospinal fluid
protein level, impaired sensation, slow nerve-conduction velocity, and distal muscle
weakness 2. In inflammatory polyneuropathies such as CIDP, early diagnosis and therapy
may not only mitigate progression of demyelination but also prevent secondary motor
unit (MU) loss, which is often responsible for persisting motor symptoms. Therefore, a
better understanding of the degree and time course of loss and stability of functioning
MUs due either to primary or secondary demyelination

3

in CIDP would provide more

insight into the pathophysiology of the disease and possibly improve functional
outcomes. CIDP affects men and women of all ages and has a population prevalence of 3
per 100,000 people 4,5.
A version of this chapter has been published. Used with permission from John Wiley and Sons, Inc.
1

Gilmore K.J, Doherty, T.J., Kimpinski, K., Rice, C.L. Electrophysiological And Neuromuscular Stability

Of persons With Chronic Inflammatory Demyelinating Polyneuropathy. Muscle and Nerve. 56 3 413-420
(2017).
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Diagnosis is based on history, clinical examination including electromyography and
nerve conduction studies, blood tests, cerebral spinal fluid, and in some cases nerve
biopsies.
Further diagnosis of CIDP is confirmed by the elimination of other neurological diseases
such as diabetic polyneuropathy and inherited demyelinating polyneuropathies. Although
the electrophysiological and neuromuscular properties of persons with CIDP have been
described above, details of undesirable alterations in motor unit structure and function
that could explain weakness and related functional changes have not been quantified
systematically. Although exact mechanisms are not understood entirely, limited evidence
in autoimmune neuropathies indicates that disease related to pre or post-synaptic damage
and muscle fiber atrophy lead to neuromuscular junction remodeling and impaired
neuromuscular transmission 6. It is presumed that in autoimmune neuropathies such as
CIDP, MU death or axonal damage is followed by variable reinnervation by collateral
sprouting and axonal outgrowth, both of which could add to neuromuscular transmission
instability 7. In routine clinical nerve conduction studies, a compound muscle action
potential (CMAP) is recorded, but the CMAP features alone do not quantify the extent of
motor unit loss or dysfunction because of the possible compensatory effect of
reinnervation. The technique of decomposition-based quantitative electromyography
(DQEMG), however, can be used to assess any loss of motor neurons and cardinally
detect the increase of motor unit size due to collateral reinnervation. DQEMG has also
been shown to be a reliable and valid tool for obtaining information regarding MU
number, size, stability, and complexity in healthy subjects, older adults, and in some

33

other neuromuscular diseases and neuropathies, such as ALS and diabetic neuropathy
8,9,10,11,12

.

A few studies in CIDP, using single fiber EMG (SFEMG) in upper limb muscles have
shown increased fiber density along with neuromuscular instability, but no studies have
investigated lower limb muscles using the DQEMG technique in CIDP patients. This
technique can extract beneficial information regarding the MU pool from simultaneously
acquired surface and concentric needle-detected signals

13

. Furthermore, in conjunction

with a maximal CMAP amplitude, DQEMG can be utilized to calculate a motor unit
number estimate (MUNE). This measure provides critical insight about the innervation
status of a muscle

10,14

. Near-fiber (NF) parameters such as jiggle, jitter, blocking, and

area, derived from DQEMG also relate to the integrity or stability of neuromuscular
transmission

12,15,16

, but these measures have not been applied to CIDP. Stability can be

examined through assessment of the degree of variability in the shape and time of
consecutively detected motor unit potentials (MUPs) termed “jiggle” and “jitter”
respectively 17.
Indeed, the assessment and understanding of these features could potentially be helpful
for treatment monitoring to aid in disease understanding. MUP shape variability
parameters and conduction blocking may provide valuable information regarding MU
health in CIDP during disease progression. Using these techniques, we evaluated the
magnitude of demyelination, collateral reinnervation following MU loss, and the stability
of neuromuscular transmission in patients with CIDP. The purpose of this study was to
assess the neuromuscular stability of the MUs in the tibialis anterior (TA) muscle of
patients with CIDP using DQEMG compared with an age- and gender-matched healthy
34

control group. We chose to focus on the dorsiflexor muscle group, because there are
comparative data available from several studies of MU properties in aging using this
muscle group and these techniques

18,19

. In addition, adequate dorsiflexor function is

critical for balance and gait and thus relate to falls risk 18. When compared with controls,
we hypothesized that patients with CIDP would feature reduced MUNEs, as well
significantly fewer stable MUs in the TA.

2.2
2.2.1

Methods
Subjects

Ten subjects (7 men, 3 women; ages 47–77 years) with CIDP volunteered for this study
as well 10 healthy control subjects (7 men, 3 women; ages 57–75 years). History, clinical,
and electrophysiological features confirming a diagnosis of CIDP were obtained by an
experienced neurologist to exclude other causes of nerve dysfunction (i.e.
radiculopathies, other polyneuropathies, or compressive mononeuropathies). Patients
with any other neurological, metabolic (including diabetes) or vascular diseases (other
than related to CIDP) were not included in this study (Table 1). All 10 patients underwent
a clinical electrophysiological examination that assessed bilateral fibular, tibial, ulnar,
and median motor nerves and bilateral sural, ulnar, and median sensory nerves. Limb
temperature was monitored during standard electrodiagnostic testing and, if necessary
limbs were warmed to a minimum of 32 degrees Celsius in the upper limb and 30 degrees
in the lower limb. Additionally, all patients with CIDP underwent measures of nerve
conduction velocities (CV), compound muscle action potentials (CMAP), and sensory
nerve action potentials (SNAP) and compared to normal values. Patients had standard
characteristics of acquired demyelination, including conduction block, temporal
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dispersion, multifocal conduction velocity slowing, and F-wave prolongation. Moreover,
CSF analysis revealed elevated protein in the absence of any other abnormality.
Furthermore, all patients had a clinical presentation consistent with CIDP without
evidence of alternative diagnosis (i.e. paraproteniemic neuropathies, multifocal motor
neuropathy or polyneuropathies). All 10 patients with CIDP received usual medical care
and responded to treatment with intravenous immunoglobulin (IVIG), plasma exchange,
or prednisone. The local university research ethics board approved the study, and
informed written and oral consent were obtained from all participants preceding testing.

2.2.2

Dorsiflexor Strength and Tibialis Anterior DQEMG Data
Acquisition

Subjects were seated in a custom isometric dynamometer designed to measure
dorsiflexion and plantar flexion function

20

. The right leg was tested, and the ankle was

positioned at 30° of plantar flexion, with both knee and hip angles maintained at 90°. A
C-shaped brace was placed firmly over the distal aspect of the right thigh proximal to the
patella to secure the leg and foot in the device for recording isometric contractions.
Additionally, over the dorsum of the foot, inelastic Velcro straps were firmly fastened to
secure the foot to the dynamometer

19

. Subjects first performed a total of 3 dorsiflexion

maximal voluntary contractions (MVCs), with a minimum of 3 min of rest between each
attempt. Each MVC was held for 3-5 s. Real time visual feedback was provided to the
subjects via a 24 inch LCD monitor. Subjects were also strongly encouraged verbally
during all contractions to ensure maximal effort. Voluntary activation during the second
and third MVC efforts was assessed using the interpolated twitch technique

21

. This

technique involves supramaximal (stimulus at 125% of peak CMAP amplitude)
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percutaneous electrical stimulation of the common fibular nerve distal to the head of the
fibula using a bar electrode. The peak amplitude of the interpolated torque electrically
evoked from a single 100μs stimulus during the plateau of the MVC was compared with
the torque produced using the same pulse delivered 1s following the MVC when the
muscle was at rest. Voluntary activation was calculated as a percent using the following
equation: [1 − (interpolated twitch /resting twitch)] × 100. The ITT provides an indication
of the voluntary ability of subjects to produce maximal dorsiflexor activation during the
MVC. Maximal torque for each participant was determined by the peak torque of the 3
MVC attempts. Torque signals were collected and sampled online at 500 Hz using Spike2
software (Version 7.11; Cambridge Electronic Design Ltd., Cambridge, United
Kingdom) and subsequently analyzed off-line to establish voluntary and stimulated
contractile properties.
Surface EMG signals were recorded from the TA using self-adhering Ag-AgCl electrodes
(1 cm × 3 cm). The active electrode was positioned over the TA motor point,
approximately 7 cm distal to the tibial tuberosity and 2 cm lateral to the anterior border of
the TA. The active electrode placement was corrected as required to minimize the rise
times and to maximize the TA CMAP negative peak amplitude. The reference electrode
was placed on the distal aspect of the TA tendon. The ground electrode was positioned
directly over the patella. DQEMG EMG data were obtained using the identical protocol
described in detail elsewhere

13,22

. To record intramuscular EMG data, a disposable

concentric needle electrode (Model N53153; Teca Corp., Hawthorne, NY) was inserted
into the TA, 5–10 mm proximal or distal to the active surface electrode. Surface and
concentric intramuscular EMG signals were bandpass filtered at 5 Hz to 1 kHz and 10 Hz
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to 10 kHz, respectively. Intramuscular EMG signals were sampled at 30 kHz, and surface
EMG signals were sampled at 3 kHz. In order to evoke a maximum TA CMAP, a bar
electrode positioned distal to the fibular head delivered supramaximal electrical stimuli
(i.e., 125% of the intensity required to achieve a plateau in amplitude) to the common
fibular nerve. Subsequently, participants matched a dorsiflexor target line of 25% MVC
for ~30 seconds using a real-time visual torque feed from the LCD monitor, while the
intramuscular concentric needle electrode was manipulated gently in the muscle. This
contraction intensity of 25% MVC of the dorsiflexors has been shown to be the most
relevant level for obtaining a representative MUNE in the TA

19

. Intramuscular and

surface EMG signals were recorded during these ~30s contractions. Between each 30second contraction, the indwelling concentric needle electrode was repositioned to
sample MUs from different regions of the muscle. These methods were repeated until a
minimum of 20 suitable MUP trains and their respective surface-motor unit potentials (SMUPs) were acquired.

2.2.3

Data Analyses

Dorsiflexor MVC torque was taken as the highest torque amplitude contraction of the 3
attempts, and the ITT was calculated as described in methods. In order to establish the
acceptability of the extracted MUP trains and their corresponding S-MUPs, the
decomposed intramuscular EMG signals were reviewed off-line. The MUP trains also
were examined visually to guarantee that their MUP occurrence patterns were consistent
with the anticipated electrical activity of a single motor unit (inter-discharge interval
duration coefficient of variation of <0.3 and a consistent firing pattern). Invalid MUP
trains and their associated S-MUPs were eliminated from subsequent analyses. The
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DQEMG algorithm calculates a MUP and S-MUP template waveforms and automatically
places markers linked to onset, negative peak, positive peak, and end positions with
respect to the MUP template, and onset, negative peak onset, end, negative peak, and
positive positions with respect to the S-MUP template. To ensure accurate marker
placement, all MUP and S-MUP markers were reviewed visually by the operator. A
motor unit number estimation (MUNE) was calculated by dividing the maximal negativepeak amplitude of the CMAP by the mean S-MUP negative peak amplitude
MUNE techniques have been reported previously for this muscle

10

14

. These

. The DQEMG

algorithms additionally provide mean-firing rates (Hz) of discrete motor units based on
their extracted MUP trains. From these MU firings an overall mean firing rate per subject
at the relative submaximal target level of contraction (25% of MVC) was estimated.
Moreover, standard parameters of the MUP template, including peak-to-peak amplitude,
duration, area, neuromuscular stability, and near-fiber parameters such as jiggle, jitter,
and percent blocking were automatically computed by the DQEMG system (see below
for details). MUPs that represent the isolated activity of a single motor unit were selected
by the algorithms for assessment of MUP stability. The selected sets of isolated MUPs
were inspected by an experienced operator, and any MUPs that were contaminated by
activity of other motor units, were removed and replaced by uncontaminated MUPs. Testretest and intra-rater and inter-rater reliability are reported to be high in control and
clinical populations using these DQEMG measures 9,11,23.

2.2.4

Near-fiber Parameters

Neuromuscular transmission integrity was determined by evaluating the degree of
variability in the shape of consecutively detected MUPs 17. Two key properties related to
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MUP shape variability are termed jiggle and jitter 17. Near-fiber (NF) jiggle refers to the
variability in overall MUP shape from 1 MUP discharge to the next. Jiggle is a statistic
that measures the shape variability of MUPs produced by a single MU

12,15

. Successful

MUP shape variability (jiggle) measurement requires the extraction of sets of “isolated”
MUPs created by a single MU. The activity of MU fibers in close proximity to the
concentric needle detection surface can be measured to determine MU stability. NF jitter
refers to the variability of the time intervals between pairs of individual muscle fiber
potentials from a single MUP 19. Both jiggle and jitter have been reported to be increased
under conditions of neuromuscular transmission disruption and axonal injury and
therefore can reflect early axonal denervation

24,25,26

. Increases in MUP instability

(assessed by jiggle and jitter) have been shown to be caused by variability in muscle fiber
action potential velocity, a finding present in various myopathies

17

. Furthermore, %

blocking was evaluated for all pairs of detected fiber contributions across the sets of
isolated NF MUPs. This parameter is calculated by measuring the number of intermittent
absences of an individual NF contribution to the NF MUPs from the set of isolated
analyzed NF MUPs 17. All of the abovementioned MUP and NF MUP parameters such as
duration, dispersion, area, and fiber count were obtained using an intramuscular
concentric needle electrode and decomposition-based quantitative electromyography
(DQEMG) software 13.

2.2.5

Statistics

Mean values ± standard deviations are presented in the text and tables. All data were
tested for normal distribution using the Shapiro-Wilk test. Data not be normally
distributed were assessed using the Kruskal-Wallis 1-way analysis of variance, whereas
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data that were normally distributed were analyzed using a 1-way ANOVA. The level of
significance for all tests was set at P > 0.05. To represent the degree of differences
between groups, effect sizes were calculated using the Cohen D.

2.3

Results

Participant characteristics are listed in Table 2.1. The two groups were well matched on
gender, age, and anthropometric indices. Patient data indicate electrophysiologic and
clinical features consistent with a diagnosis of CIDP (Table 2.2). There were no gender
differences on any parameter measured in this study. Dorsiflexion strength, voluntary
activation (ITT), standard MUP parameters, and MUNE values are listed in Table 2.3.
NF MUP parameter values are presented in Table 3. NF jiggle values are listed as a
percentage. During MVCs, both the patients and controls were able to achieve nearmaximal (>95%) voluntary activation as assessed using the ITT. The patients with CIDP
had smaller CMAPs compared to controls. Patients also had fewer motor units (−27%)
and were weaker (−37%) than controls despite being fully activated during voluntary
efforts. When assessing MU stability, the patients with CIDP had 90% more jiggle and
44% more jitter indicative of greater neuromuscular transmission instability when
compared to controls (Table 2.4). Patients also had significant transmission blocking
compared to controls (400% difference vs 0%, respectively). Patients with CIDP had
greater: NF area (+26%), NF duration (+55%), NF dispersion (+106%), and maximal NF
interval (+70%) compared to controls. Patients also had increased (+48%) fiber count.
Figure 2.1 depicts exemplar data of near-fiber motor unit potential train (MUPT) data
from control (a) and a subject with CIDP (b). The NF MUP rasters show sequential
firings of motor unit potentials. The NF MUP shimmer plots are an overlay of MU firings
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from a single MU. From these results, those with CIDP had significantly less strength but
were fully activated during maximal voluntary efforts. Patients with CIDP also had
substantially lower CMAP values and fewer numbers of MUs with increased
neuromuscular instability and blocking compared with controls.
Table 2.1 Participant characteristics
Anthropometric parameters

Controls (n = 10)

Patients with CIDP
(n = 10)

Men/Women

7/3

7/3

Age (years)

66.5 ± 9.2

60.5 ± 10.3

Height (cm)

170.0 ± 1.0

170.4 ± 1.2

Mass (kg)

79.3 ± 13.3

80.5 ± 11.5

BMI (kg/m2)

26.7 ± 2.9

27.8 ± 4.9

There were no significant differences (P>0.05) in any parameter. BMI- Body mass index
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Table 2.2 CIDP clinical classification
Patient

Duration

MRC

CSF level

C

T

F-Wave

Response to IVIG

(M,F,

of CIDP

score

(g/isolation)

B

D

prolongati

or Prednisone

age)

(y)

(out of 5)

F, 59

8

3/5

3.3







75g/ 3weeks IVIG

M, 61

22

1/5

1.5





-

80g/ 4 weeks IVIG

M, 63

6

4/5

0.75







20g/ 3 weeks IVIG

M, 73

6

4/5

0.6







Plasma exchange/

on/latency

2 weeks, 125 mg
prednisone daily

F, 62

5

3/5

0.85





-

55g/ 3 weeks IVIG

M, 68

3

4/5

0.7



-

-

20g/ 2weeks IVIG

M, 60

12

4/5

-







currently not
treated

M, 45

20

2/5

-







20 mg prednisone
daily

F, 59

10

5/5

2.9







5mg prednisone
every other day

F, 58

12

4/5

6.6







55g/ 4weeks IVIG
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CSF- Cerebral spinal fluid; IVIG- Intravenous immunoglobulin; - represents no value;  - value observed;
CB - Conduction block; TD - Temporal dispersion, M-Male, F-Female

Table 2.3 Dorsiflexor strength and tibialis anterior MUP and MUNE parameters.
Parameter

Controls

Patients with CIDP

% Difference

(n = 10)

(n = 10)

Dorsiflexion MVC strength (Nm)

33.6 ± 7.7

21.2 ± 2.9*

−37%

Voluntary activation (%)

95 ± 3

95 ± 2

–

MU firing rates (Hz) at 25%

12.10 ± 1.80

9.8 ± 0.9

−19%

MUP Vpp (μV)

811.8 ± 233.6

1081.3 ± 259.4*

+32%

MUP duration (ms)

12.6 ± 2.1

18.9 ± 4.6*

+47%

MUP area (μVms)

1443.2 ± 531.4

1636.4 ± 517.8

+13%

AAR (ms)

1.75 ± 0.2

2.2 ± 0.5*

+20%

Shape width (ms)

0.7 ± 0.1

0.7 ± 0.2

–

Turns (#)

2.6 ± 0.8

4.1 ± 1.2*

+58%

CMAP (mV)

6.9 ± 0.83

2.9 ± 0.9*

−57%

mSMUP (μV)

73.3 ± 12.8

84.0 ± 20.1

+13%

MUNE (#)

99 ± 15

72 ± 9.6*

−27%

MVC

MVC, maximal voluntary contraction; MU, motor unit; MUP, motor unit potential; Vpp, peak-to-peak
voltage; AAR, area to amplitude ratio; CMAP, compound muscle action potential; mSMUP, mean surface
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motor unit potential; MUNE, motor unit number estimate; -, no value. * significant difference vs controls
(P < 0.05).

Table 2.4 Neuromuscular transmission stability and near-fiber parameters.

Parameter

Controls

Patients with CIDP

% Difference

(n = 10)

(n = 10)

Contractions (#)

4.2 ± 0.5

6.6 ± 1.0*

+57%

# of MUPTs/contraction

5.0 ± 0.4

4.1 ± 1.2

-18%

NF area (kV/s2ms)

6.9 ± 1.9

8.8 ± 1.3*

+26%

NF duration (ms)

3.8 ± 0.6

5.9 ± 1.4*

+55%

NF dispersion (ms)

1.7 ± 0.4

3.5 ± 1.0*

+106%

Max NF interval (ms)

1.0 ± 0.2

1.7 ± 0.5*

+70%

NF fiber count (#)

2.5 ± 0.4

3.7 ± 0.7*

+48%

NF jiggle (%)

34.3 ± 3.7

65.1 ± 7.2*

+90%

NF jitter (μs)

39.7± 9.5

57.1 ± 6.4*

+44%

% Blocking

0.0 ± 0.0

4.1 ± 1.4*

+400%

MUPT - motor unit potential train; NF - near-fiber. * significant difference between patients with CIDP and
controls (P < 0.05). Conduction block in patients was 4 times greater than controls, represented by a 400%
difference.
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Figure 2.1 Motor unit potential train raster plots
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Exemplar data of near-fiber MUPTs raster plots created from accelerated data from a control subject (A)
and a patient with CIDP (B). The rasters show sequential firings of MUPs. The NF MUP shimmer plots are
an overlay of MU firings from a single MU. NF jiggle values are shown as a percentage.

2.4

Discussion

In this study we found that individuals with CIDP showed marked differences in many
neuromuscular measures in the tibialis anterior. Despite being age- and gender-matched
and with equal voluntary activation abilities, dorsiflexor strength was 37% less in CIDP,
and the TA in patients had 27% estimated fewer motor unit numbers which were
considerably less stable with greater blocking compared to controls. Our results of
MUNE and strength parameters are comparable to other studies of diseased
neuromuscular systems. For example, Allen et al., (2015)

10

reported 60% fewer motor

units and a 60% difference in strength in a diabetic polyneuropathy population compared
to healthy controls. The number of motor units estimated by MUNE can be lower either
because of axonal loss or because of loss of function of selected axons due to conduction
block. Our data show fewer MUNEs, greater NF jiggle, NF jitter and blocking in patients
with CIDP in comparison to controls and may reflect the pathological alterations in
neuromuscular transmission instability or decreased neuromuscular action potential
propagation (Table 3). Greater neuromuscular transmission instability is believed to arise
in conjunction with incomplete reinnervation occurring between orphaned muscle fibers
and their adopted axonal sprouts throughout the course of collateral reinnervation, or with
partial loss of innervation by a damaged motor axon, 17. Additionally, our data quantified
neuromuscular transmission failure (i.e., % blocking) in patients compared to controls
(Table 2.3). This intermittent transmission failure indicates an underlining dysfunction
related to neuromuscular transmission, and this would then lead to increased NF jiggle
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and NF jitter. Furthermore % blocking is indicative of the rate at which an individual
muscle fiber fails to propagate an action potential following activation of its motor
neuron. However, it is not certain how potential dysfunction at any of these sites (the
neuromuscular junction, muscle fiber action potential propagation, distal axonal
branches, or a combination of factors) contribute to decreased neuromuscular stability in
CIDP.
Studies using animal models suggest that neuromuscular instability could be due to a
variety of factors including axon terminal dysfunction 27, nerve demyelination or reduced
axonal caliber 28, structural changes in the muscle fiber 27,29, ion channel alterations 27,30,31
and other possible mechanisms. Any of these proposed alterations in muscle fibers could
potentially adversely impact muscle fiber action potential conduction velocity

32

and

subsequently affect MUP shape stability. Our findings of increased NF dispersion, NF
duration, fiber count, and max NF interval in CIDP likely indicate that prior
compensatory reinnervation has occurred due to muscle fiber denervation

12,33

. MUNE

techniques have been used in several studies of amyotrophic lateral sclerosis (ALS)
34,35,36

40

. However, there are very few studies conducted specifically on polyneuropathies

. Mostly these studies have focused on hereditary polyneuropathies

38,39,40,41

. Two

studies in patients with CIDP that used single fiber EMG (SFEMG) in upper limb
muscles reported abnormalities and increased fiber density

42,43

and transmission

instability 42 compared with controls. Using stimulated SFEMG, another study reported
that there was intermittent or persistent blocking in the nerve fibers in upper limb muscles
of patients

44

. Moreover, Delmont et al (2016) showed that patients with CIDP have

fewer motor units than controls in the TA using the motor unit number index (MUNIX)
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technique

45

. They suggested the lower MUNIX was a sign of axonal loss or loss of

functioning axons and an increase in the average motor unit size (SMUP and MUSIX)
probably due to the compensatory effect of reinnervation. Lastly, another study that used
MUNIX and multi-point stimulation showed that the MUNIX value was lower in the
abductor pollicis brevis (APB) muscle when compared with healthy controls in CIDP 7. It
is not possible to compare directly various MUNE methods and MUNIX because of the
specific differences in the technical and physiological aspects in each method. MUNIX is
an “index” which reflects the number of motor units, using the power and area of CMAP
and interference patterns, whereas DQEMG is more invasive but provides direct
recordings of MU properties, including neuromuscular stability. Thus, by incorporating
needle-detected signals our study provides further insight into factors that may affect MU
function in relation to neuromuscular function and stability that may indicate the degree
of disease involvement and disease severity.
Quantification of neuromuscular stability, specifically NF jiggle and NF jitter in patients
with CIDP, has not been reported systematically. However, in other clinical conditions
such as ALS, higher jiggle values were found in the small number of MUPs studied

17

,

and in patients with myasthenia gravis higher jiggle values were reported 26. Additionally,
increased jiggle was found in patients with diabetic neuropathy 12. Our findings of higher
jiggle in CIDP align with these other studies, although the mechanisms responsible may
be quite different (i.e diabetic polyneuropathy and CIDP). It has been shown that
instability in the neuromuscular system negatively affects neuromuscular transmission
propagation and can have corresponding detriments on strength

12

. Our finding that

patients with CIDP have increased blocking is supported by Stalberg and Trontelj, who
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showed increases in transmission blocking in myasthenia gravis using SFEMG

46

. Our

data showing increased NF jiggle and NF jitter in patients relative to controls may reflect
pathological alterations in neuromuscular action potential propagation or neuromuscular
transmission instability, but it is difficult to ascertain a prime site. Our percent blocking
results are also similar to Allen et al., (2015)

10

, in diabetic neuropathy and indicate

failures in muscle fibers to propagate their signal after excitation of a spinal motor neuron
12

.

2.5

Conclusion

We have demonstrated the utility of concentric needle-derived DQEMG for detection of
motor unit remodeling and differences in neuromuscular transmission instability when
comparing patients with CIDP with age and gender-matched controls. This study
highlights the value of DQEMG as a potential measure that is sensitive to changes not
currently detectable by standard clinical nerve conduction studies associated with CIDP.
The results of this study suggest that NF MUP parameters may have usefulness in
tracking CIDP progression or the degree of physical impairment. The existence of
neuromuscular transmission failure (i.e. blocking) in patients may have significant
consequences regarding neuromuscular function under circumstances that stress the
capacity of the neuromuscular system, such as contractions that are fatiguing. Finally,
the outcomes of our study indicate that NF jiggle and NF jitter are valuable indices for
identification of alterations in the early stages of neuromuscular disease, preceding the
loss of motor units or onset of muscle atrophy. Further longitudinal studies of patients
with CIDP undergoing treatment regimens using the stability parameters of jiggle and
jitter may be helpful in improving the understanding of the disease.
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Chapter 3

3

1

Abnormal Motor Unit Firing Rates In Chronic Inflammatory
Demyelinating Polyneuropathy
3.1

Introduction

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune mediated
disorder of peripheral nerves, with predominant motor involvement and progression over
several months. In some patients with CIDP the disease course is monophasic with
complete recovery, and in others it can be slowly progressive, or relapsingremitting resulting in prolonged morbidity and sometimes-permanent disability 1. Even
with appropriate treatment, CIDP usually results in multifocal and segmental
demyelination that induces motor unit (MU) loss over time 2. The primary goals of
treatment management are to control the state of inflammation and thus reduce peripheral
axonal loss and consequential atrophy, weakness and disability.
It is well established that functioning numbers of motor units as well as the motor unit
firing rate characteristics influence the generation and control of muscle force, however
this has not been systematically investigated in patients with CIDP. Skeletal muscle
composition and some MU physiological properties have been described in Amyotrophic
Lateral Sclerosis (ALS) including the finding that mean motor unit firing rates were
higher in patients with dominant lower motoneuron (LMN) dysfunction compared to
controls.
A version of this chapter has been accepted for publication in the Journal of the Neurological Sciences
1

Gilmore K.J, Kirk E.A, Doherty T.J, Kimpinski K, Rice C.L. Abnormal Motor Unit Firing Rates In

Chronic Inflammatory Demyelinating Polyneuropathy.
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Conceivably this was due to compensatory mechanisms needed to achieve the desired
force accounting for a loss of MUs 3. MU firing rates were lower in patients with ALS
with dominant upper motoneuron (UMN) features probably due to diminished central
drive 3. In addition to alterations in mean firing rates, it has been shown that patients with
ALS have greater motor unit firing rate dysfunction and increased motor unit firing rate
variability, specifically in ALS patients with dominant UMN dysfunction.
The few studies focused on MU function, demonstrated that individuals with CIDP have
fewer MUs than control subjects in the tibialis anterior muscle 2. Furthermore, severe
disruptions in action potential propagation have been demonstrated by concentric needle
detected jitter and jiggle values that were greater than controls, as well as the presence of
neuromuscular junction blocking

4,2

. The losses in motor axons as well as the instability

seen in the neuromuscular junctions of patients with CIDP may have precipitated the loss
of total muscle mass and the infiltration of non-contractile tissue in the leg musculature 5.
Overall, these changes to the neuromuscular system likely contribute to functional
weakness and disability in individuals with CIDP.
Functional impairment in patients with CIDP is primarily caused by conduction block
and chronic denervation that leads to muscle atrophy and weakness. However, in addition
to this, it is fundamental to study the motor unit firing characteristics to garner a fuller
understanding of the etiology of muscle weakness in patients with a chronic peripheral
demyelinating disease. Furthermore, because individuals with CIDP demonstrate a length
dependency with regard to axonal loss, often affecting gait and balance, we chose to
investigate a leg muscle, the tibialis anterior. Fewer motor units, skeletal muscle loss as
well as neuromuscular blocking or slowed axonal transmissions have previously been
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reported for this muscle

2

and therefore we expect firing rates to be impaired and

recruitment of motor units to be the main strategy used for force gradation at higher
contraction intensities in patients with CIDP.

3.2

Methods

3.3

Subjects

Seven control (4 male/3 female) subjects and eight (6 male/2 female) patients with CIDP
were recruited for the study (Table 1). All control subjects were healthy, living
independently and medication free. Control subjects were recreationally active but not
trained systematically. Exclusion criteria included known neuromuscular or orthopaedic
disorders of the lower limb, diabetes, excessive alcohol use, caffeine consumption prior
to participation, and recreational drug use. This study was reviewed and approved by the
local University's research ethics board for human experimentation and conforms to the
latest revision of the Declaration of Helsinki.

3.3.1

Patient Electrodiagnostic Criteria

All individuals with CIDP were diagnosed based on the criteria established by the
European Federation of Neurological Societies 6. Patients with any metabolic (including
diabetes), neurological, or vascular diseases (other than related to CIDP) were excluded
from this study. Clinical electrodiagnostic evaluation included standard motor studies of
the median, ulnar, tibial, and fibular nerves. All patients had electrodiagnostic testing and
all patients demonstrated demyelinating features (increased temporal dispersion, or
conduction block, onset latencies/conduction velocities in the demyelinating range) at the
time of diagnosis (Table 3.2). Standard clinical measures of cerebral spinal fluid (CSF),
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compound muscle action potential (CMAP) amplitudes, nerve conduction velocities, and
sensory nerve action potential amplitudes (SNAP) were compared to normative values to
substantiate a diagnosis of CIDP. Moreover, all patients with CIDP received standard
medical care and responded to treatment with intravenous immunoglobulin (IVIG), oral
prednisone or plasma exchange (Table 3.2).

3.3.2

Strength and Experimental Set-up

All data were collected during one testing session with one control subject returning for a
second visit to collect a sufficient number of action potential trains for firing rate
measures. To record voluntary strength of the dorsiflexors, subjects were seated upright
in a dynamometer (Cybex HUMAC NORM; CSMi Medical Solutions, Stoughton, MA)
with the right leg fixed to an adaptor arm with the right ankle positioned at 30° of plantar
flexion, while both knee and hip angles were maintained at 90°. Inelastic fastenings were
wrapped over the dorsum of the foot to secure it to the dynamometer ensuring no aberrant
movement. Control and patients with CIDP performed three to five dorsiflexion MVCs,
with at least five min of rest between each attempt. All subjects were instructed to
contract as hard and as fast as possible to ensure maximal rate of torque were achieved.
Each MVC was held for three to five seconds.

3.3.3

Electromyography

Surface electromyography (sEMG) signals were recorded from the TA using selfadhering Ag-AgCl electrodes (1 cm × 3 cm). The active electrode was positioned over
the TA motor point, approximately seven cm distal to the tibial tuberosity and two cm
lateral to the anterior border of the TA, with the reference was placed over the patella. All
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sEMG signals were preamplified (×1,000), wide-band filtered between 10 Hz and 10 kHz
(Neurolog, NL844; Digitimer), and sampled at 2 kHz (Power 1401; Cambridge
Electronic Design).
Intramuscular EMG signals were recorded during voluntary isometric contractions using
two intramuscular tungsten electrodes

7,8,9

. The electrodes were commercially available

insulated tungsten needles (123 μm in diameter and 45 mm in length (FHC, Bowdoin,
ME). After sterilization, these electrodes were inserted into the tibialis anterior muscle
with one needle inserted distally in the TA muscle belly, and the other proximally (7-9
cm distal to the patella). The two intramuscular electrodes were connected to separate
channels, and each needle was manipulated independently by an experienced operator.
This allows the needle operator to sample at each contraction intensity from various
discrete MUs, from different regions and depths of the muscle in order to build a
representative MU profile. The intramuscular EMG signals were pre-amplified (×100)
and wide-band filtered between 10 Hz and 10 kHz and sampled at 20 kHz per channel.
The surface ground electrodes for the intramuscular recordings were positioned over the
patella of the tested limb. Live visual and audio feedback of intramuscular EMG signals
were provided to each operator independently.
Multiple voluntary contractions were held for five to ten seconds at each of the three
contraction levels (25%, 50%, 75%), whereas MVCs were held for three to five seconds.
The order of contraction intensity was randomized. MU action potential trains were only
included when sampled during the steady-state torque plateau of each voluntary
contraction (Figure 3.1). To sample from many different isolated MUs over the series of
voluntary contractions, the intramuscular tungsten electrodes were maneuvered and
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advanced slowly through the muscle in increments of ∼0.5 cm or less per voluntary
contraction. Verbal encouragement was provided, and live visual feedback of force was
displayed to each subject during all voluntary contractions. Fatigue was minimized by
providing adequate rest (3-5 minutes) between contractions and the session ended when
an MVC contraction was >5% lower than the baseline MVCs.

3.3.4

Data Analysis and Statistics

MU analyses were performed offline with Spike2 (Cambridge Electronic Design;
Cambridge, UK) as described previously 8,9,10,11. To confirm spikes belonged to the same
specific MU, each MU was first analyzed using a template shape algorithm, and then
visually inspected by an experienced operator 7. To be accepted, rigorous inclusion
criteria were applied and in addition to shape overlay of MU potentials a minimum of
five consecutive contiguous action potentials (four inter-spike intervals) was required for
each acceptable MU train. Additionally, a coefficient of variation of <30% for the interspike intervals of each MU train was required for a train to be included in the analysis 12.
Any doublet firings (>100 Hz) were not included in the MU analysis. An example of two
discrete MU action potential trains extracted during an MVC from a control subject is
provided (Figure 3.1). It should be noted that the needle electrode was slowly advanced
during each contraction and thus there are small variations in the amplitude and shape of
the successive action potentials and inherent small temporal differences in the timing of
each firing. However, the characteristic unique ‘signature’ of each firing was the critical
feature used to determine a single train of action potentials arising from one MU and
independent from other units. To statistically compare MU trains between controls and
patients, trains were grouped into four bins based on torque contraction level: a 25% bin

63

included units ranging from 12.5 - 37.5 % MVC, a 50% bin was from 37.5 % - 62.7%, a
75% bin was from 62.5% - 85%, and 100% bin contained torque levels between 85% –
100% of MVC 9. To assess surface EMG, 1.5 second time epochs were measured during
the steady-state torque portion of all four voluntary contraction intensities. The
electromyographic root-mean-square (EMG-RMS) amplitude during MVC torque was
used to normalize surface EMG for the 25, 50 and 75% contraction intensities. To
determine statistical significance between CIDP and controls Chi square calculations
were performed on contraction bins to measure how expected outcomes compare to
observed data.
The R software program (version 3.6.1) was used for statistical analyses. Anthropometric
data were compared using unpaired two-tailed t-tests. Pearson correlation coefficients
were calculated for all mean MU firing rates dependent on MVC% for CIDP and control
group. Random intercept mixed linear regression models were used to compare mean
MU firing rates between control subjects and patients with CIDP for each voluntary
contraction intensity bin using the lme4 package

13

. To normalize data, mean MU firing

rates were log-corrected, with null and full models with the subject as random effect
estimates. The MVC%, MU train length, standard deviation of the firing rate means and
the coefficient of variation of the mean firing rate were defined as fixed effect estimates.
The models were a subset based on targeted contraction bins, with the Likelihood Ratio
Tests performed to compare the effect of CIDP. Statistical significance was set to P ≤
0.05.
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3.4

Results

Mean age and anthropometric indices were not different between groups (Table 3.1).
Patients with CIDP were 33% weaker for dorsiflexor MVC strength when compared with
controls (Table 3.1). The intramuscular EMG sampling of voluntarily activated MUs
yielded a total of 1389 MU action potential trains, with 664 from individuals with CIDP
and 725 from control subjects (Figure 3.2). There are apparent differences in the scatter
plots, depicting each MU firing rate as a discrete sample between control and CIDP
groups (Figure 3.2). Although rates are higher in the CIDP group at the lower (25%
MVC) contraction intensity compared to controls, the mean firing rates of binned units
were not higher at intensities of 75 and 100% MVC. This resulted in a weak negative
correlation with %MVC (r = -0.20 95% confidence interval = -0.27–-0.13, t = -5.37, p
value = 1.08e-07) for the CIDP group. Results from the control group contrasted with the
findings in the CIDP group, and showed a strong positive correlation between MU firing
rate and MVC% (r = 0.78 95% confidence interval = 0.75-0.84, t =33.9, p value < 2.2e16).
When mean MU firing rates were grouped based on target contraction intensities,
histograms show the distributions of sampled MU firing rates grouped by contraction
intensity up to MVC (Figure 3.3). Notably, very few MU firing rates occurred above 30
Hz in the CIDP group. When the firing rate distributions at 75% and 100% of MVC were
compared in the two groups, the rates in the CIDP group were significantly lower. At
25% of MVC, the patients with CIDP demonstrated a higher MU firing rate range and a
shifted distribution to higher MU firing rates. To test the effect of CIDP on MU firing
rates a mixed linear regression analysis was used to compare each targeted contraction
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bin (Figure 3.2). Both groups were equally capable of targeting the various MVC
intensities (Table 3.3) and mean MU firing rates of patients with CIDP were higher at the
lowest contraction intensity bin of 25% MVC (X2 = 15.9, df = 8, p value = 6.6e-05).
Whereas, at the two highest contraction intensity bins, the firing rates in patients with
CIDP were lower in comparison to controls (75 % of MVC; X2 =30.6, df = 8, p value =
3e-08; 100% of MVC X2 = 42.2, df = 8, p value = 8.1e-11). There was no difference at
50% of MVC between the control group and the patients with CIDP and this finding is
further supported by the similarity between mean values (Table 3.3) and distribution
ranges (Figure 3.3). Surface EMG (normalized to MVC) indicated that both groups had a
positive linear relationship between contraction intensity bins and sEMG. However,
sEMG was lower (P < 0.05) in patients with CIDP when compared with control subjects
at 50 and 75% MVC (Table 3.3).

66

Table 3.1 Subject characteristics
Anthropometric parameters

Controls (n = 7)

Patients with CIDP (n = 8)

Men/Women

4/3

6/2

Age (years)

58.0 ± 8.3

59.2 ± 6.5

Height (cm)

152.0 ± 6.0

163.0 ± 4.0

Mass (kg)

73.5 ± 9.4

79.4 ± 11.3

BMI (kg/m2)

25.3 ± 2.8

27.8 ± 4.8

Dorsiflexion MVC strength (Nm)

44.2 ± 4.8

29.8 ± 3.4*

BMI- Body mass index, MVC- maximum voluntary contraction *P < 0.05
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Table 3.2 CIDP clinical features
Patient

Duration

MRC

CSF

(M/F,

of

score

age)

treatment

(out of 5)

(y)
M, 61

22

CB

TD

F-Wave

Treatment IVIG

protein

prolongati

or

level

on/latency
Prednisone

(mg/dL)
1/5

150





-

80g/ 4 weeks
IVIG

M, 63

6

4/5

75







20g/ 3 weeks
IVIG

M, 73

6

4/5

60







Plasma
exchange/ 2
weeks, 125 mg
prednisone daily

M, 68

3

4/5

70



-

-

20g/ 2weeks IVIG

M, 45

20

2/5

-







20 mg prednisone
daily

F, 59

10

5/5

290







5mg prednisone
every other day

M, 60

12

4/5

660







55g/ 4weeks IVIG

F, 58

12

4/5

96







80g/3weeks IVIG,
10mg prednisone
daily

MRC score of ankle dorsiflexion, CSF- Cerebrospinal fluid; IVIG- Intravenous immunoglobulin, M-Male,
F-Female

68

Table 3.3 Motor unit data
Parameter

CIDP

Control

Targeted

25

50

75

100

25

50

75

100

MVC %

23.8 ± 3.8

46.8 ± 5.2

73.3 ± 5.5

94.3 ± 5.7

24.2 ± 5.4

47.2 ± 8.4

74.3 ± 6.6

96.2 ± 3.9

Discharge

18.8 ± 1.1*

16 ± 6.3

18.1 ± 2.0*

17.1 ± 1.7*

13 ± 2.3

18.2 ± 4.4

31.6 ± 3.8

40.1 ± 2.3

189

162

140

129

202

186

155

141

10.7 ± 5.4

13.2 ± 4.2

9.7 ± 2.5

8.5 ± 3.8

10.2 ± 3.6

10 ± 4.1

9.3 ± 3.3

9.9 ± 4.4

10.2 ± 4.1

12.4 ± 3.1

13.8 ± 2.6

15.2 ± 3.6

10 ± 3.5

11.1 ± 2.4

13.2 ± 3.9

14.1 ± 2.8

23.2 ± 6.8

44.8 ± 8.9*

68.4 ± 9.5*

100 ± 0

26. 4 ± 8.8

51.6 ± 10.2

77.4 ± 12.5

100 ± 0

MVC %

rate Hz

No. MU
trains

No. of ISIs
per MU train

Coefficient
of Variation
%

sEMG %

Values are means ± SD. MVC, maximal voluntary isometric contraction, ISI- interspike interval, EMGRMS- electromyography – root mean squared *P < 0.05 for interactions between control and CIDP
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Figure 3.1 Example of tungsten needle recording during a contraction
A: Unprocessed tibialis anterior needle electromyography (EMG) recordings collected through tungsten
electrodes from a healthy control subject. B: Examples of action potential shape and overlay of all action
potentials from 2 identified motor unit (MU) trains. MU1 is an overlay of 9 action potentials with a
coefficient of variation of 10.3, discharging at 21.8 Hz. MU2 is an overlay of 20 action potentials with a
coefficient of variation of 8.8, discharging at 31 Hz. C: Raw torque tracing from a maximal voluntary
contraction (MVC).
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Figure 3.2 Scatter plot of MUFR
Scatterplots of 1,389 individual motor unit action potential trains with 725 from the control subjects (A)
and 664 from patients with CIDP (B).

71

Figure 3.3 Histograms of MUFR means
Bars represent mean motor unit firing rates. Panel A is firing rates from a 25% contraction, B is 50%, C
75% and D are firing rates from maximum voluntary contractions (100%). Exact values are found in Table
3.3.

3.5

Discussion

In this study we demonstrate that individuals with CIDP, in comparison to an age- and
sex-matched healthy group, are 33% weaker in dorsiflexor strength and show distinct
alterations in MU firing rates of the tibialis anterior from low to maximal intensity
voluntary dorsiflexion contractions. Patients with CIDP had significantly higher motor
unit firing rates than controls at a low contraction intensity (25% MVC) and these MU
firing rates remained minimally changed at higher contraction intensities (75, 100%
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MVC). Conversely, the control group showed increasing rate modulation as contraction
intensity was increased, and at MVC the MU firing rates were approximately 55% higher
than patients with CIDP. Both control subjects as well as patients with CIDP, had linear
increases in surface EMG with increased voluntary isometric contractions. This finding is
in agreement with the literature in that there is usually a positive or approximate linear
relationship between torque and surface EMG

14

. However, the patients with CIDP had

significantly less normalized sEMG at 50 and 75% MVC compared with controls. Thus,
for force gradation from lower to higher contraction intensities patients with CIDP may
rely more on recruitment than rate coding. In conjunction, perhaps because patients with
CIDP have an overall loss of MUs 2, the patients have fewer units to recruit and thus have
lower sEMG specifically at the higher contraction intensities when recruitment of larger
MUs normally is required.
Our results are the first to investigate the firing characteristics of motor units in relation
to a chronic peripheral demyelinating disease and may suggest that some degree of
blocking of action potentials may be occurring along the axons, at the neuromuscular
junction or potentially due to disruptions within the muscle fibers making the fibers
unable to transmit high frequency (>30Hz) trains of action potentials. Studies using
animal models suggest that neuromuscular blocking in patients with CIDP could be due
to a variety of factors including reduced axonal caliber, axon terminal dysfunction, ion
channel alterations, structural changes in the muscle fiber and other possible mechanisms
all related to chronic nerve demyelination

15,16

. Any of these proposed alterations in

muscle fibers could potentially adversely impact muscle fiber action potential conduction
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propagation, velocity

17

and consequently affect MU firing rates of action potentials that

do reach the muscle fibers.
Muscle weakness is a cardinal feature of patients with CIDP, and in prior studies we
reported that muscle quantity and quality are lower compared with control subjects and
may account for much of the weakness

18,5

. A component of lower skeletal muscle

quantity and quality in patients with CIDP could be related to denervation and
reinnervation from fewer numbers of MUs as shown previously 2.

Another study

reported that when muscle from patients with CIDP was normalized to contractile crosssectional area, individuals with CIDP still demonstrated weakness compared to healthy
controls 18. This indicates that despite accounting for non-contractile tissue from patients
with CIDP, there remain inherent structural disruptions to the contracting proteins. Our
results here indicate that lower firing rates in patients with CIDP at higher contraction
intensities may also be a significant contributing factor to muscle weakness.
Two studies of patients with CIDP, that used single fiber electromyography (SFEMG) in
upper limb muscles reported abnormalities including increased fiber density and
transmission instability compared with control subjects 15,16. Using stimulated SFEMG, it
was determined that there was intermittent or persistent blocking in nerve fibers in the
upper limb muscles of patients with CIDP

16

. A study by Gilmore et al., (2017)

investigated the number of MUs as well the stability of these MUs in individuals with
CIDP in the tibialis anterior muscle. That study demonstrated that individuals with CIDP
had fewer motor units, with greater neuromuscular instability and motor unit discharge
blocking in comparison to healthy aged and sex matched controls. As a consequence of
peripheral nerve demyelination neuromuscular instability may reflect the pathological
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alterations in neuromuscular transmission or decreased neuromuscular action potential
propagation along the axon. Moreover, increased MU firing rates are often observed
during routine needle EMG studies performed by clinicians in patients with peripheral
neuropathies, however contraction intensities rarely exceed 25% in this setting, which
does not allow for the observation of failure of rate modulation at higher contraction
intensities 19.
In addition to differences in mean firing rates, at low levels of contraction, patients with
CIDP did not have MU firing rates (MUFR) above 30Hz whereas rates greater than 40Hz
were observed in control participants at 75% and 100% of MVC. These results
demonstrate that MUs that would normally be active at high force levels are absent due to
MU loss, or conversely these later recruited larger MU have a physiological propagation
block or have undergone intrinsic changes in the motor neuron properties resulting in the
inability to fire at these highest rates.
Based on these observations it appears that force modulation beyond 25% MVC in
patients with CIDP is mainly reliant on recruitment. However, these MUs that are later
recruited may not have adequate firing rates to reach the necessary tetanic force.

3.6

Conclusion

These findings of altered motor unit firing rates and possible motor unit block in patients
with CIDP may be fundamental in explaining some of the functional consequences
related to weakness and atrophy. The inability of muscles to receive normal higher
frequencies of excitation occurring over many years may have contributed to changes in
muscle size and quality

18

ultimately contributing to some of the muscle weakness in
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CIDP patients. Indeed, it is known that chronic low frequency muscle excitation will
lead to dramatic detrimental changes on muscle properties

20,21

. Perhaps if muscles in

patients with CIDP, stop receiving rates of excitation beyond 30 Hz the muscle will
respond and change its properties accordingly.

Importantly, studies examining

microscopic muscle architecture in patients with CIDP would further elucidate the result
of nerve demyelination on specific muscle composition.
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Chapter 4

4

1

Reductions In Muscle Quality And Quantity In CIDP
Patients Assessed By Magnetic Resonance Imaging
4.1

Introduction

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an inflammatory
peripheral nerve disorder with sensory disturbances and progressive muscle weakness in
both the proximal and distal extremities. Most studies on neuroinflammatory diseases,
such as multiple sclerosis and inflammatory myelopathies, have focused on the detection
of specific neurological lesions using MRI

1,2

. Indeed, nerve lesions in patients with

CIDP have been shown by MR imaging in the lumbar nerve roots (L4 and L5), tibial
nerve, and brachial plexus

3,4

. In one study the lumbar nerve roots using MRI were

evaluated in both treated and untreated CIDP patients and in those with polyneuropathy
due to other etiologies. They reported that MRI was useful in identifying nerve root
hypertrophy, and as an adjunct test to identify CIDP in situations in which the diagnosis
was uncertain 5. Furthermore, using another MRI technique Sinclair et al 6 demonstrated
that magnetization transfer ratio (MTR) in the posterior leg muscles of patients with
CIDP was significantly lower than controls, indicating that hydration changes or subtle
biochemical disparities within the leg musculature had occurred in the chronic
degenerative disease stage of CIDP.
A version of this chapter has been published. Used with permission from John Wiley and Sons, Inc.
1

Gilmore K.J, Doherty, T.J, Kimpinski, K, Rice, C.L. Reductions In Muscle Quality And Quantity in CIDP

Patients Assessed By Magnetic Resonance Imaging. Muscle Nerve. 58 3 396-401 (2018).
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Moreover, this study also established that lower MTR values in the anterior compartment
of the leg correlated strongly with diminished ankle dorsiflexion strength.
The loss of strength in muscles of those with CIDP is most severe distally, can be
profound 7 and likely has a direct significance on functional impairments. However, very
little data exists regarding the limb musculature in persons with CIDP, specifically
muscle quantity and quality. A few studies have reported correlations between MRI
detected nerve impairments and clinical findings (e.g., muscle strength and impairment)
8,9

. Although force (strength) is strongly associated with the quantity of muscle tissue

that is accessible for measurement, there are essential qualitative muscle properties
involved that may also severely affect muscle strength 10. Muscle quality can be defined
as strength per unit of muscle mass as assessed by MR imaging methods, and is usually
assessed by normalizing strength to cross-sectional area 11 or to total muscle volume 12,13.
When muscle strength is normalized to tissue amount and strength deficits persist, this
indicates deficiencies in contractile quality. Transverse magnetization (T2) relaxation
time is a quantitative MRI sequence sensitive to small changes in proton density of a
tissue. For example, when skeletal muscle atrophies with ageing or disease, a concurrent
increase in non-contractile tissue, such as connective tissue and adipose tissue is
deposited intramuscularly. Thus, in aging T2 relaxations times increase from 31ms in
young adults to 42ms in those over 60 years

14

. Increased T2 relaxation times therefore

can reflect reduced contractile muscle tissue density contributing to muscle weakness 15.
T2 weighted images and general anatomical MR scans are beneficial beyond calculating
strength per unit mass, as they also provide a complementary understanding of tissue
density and muscle protein structural integrity 16. In CIDP, it is sensible to postulate that
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muscle weakness may be caused by reductions in both quantity and quality of skeletal
muscle, but to date, no studies have investigated these features comprehensively.
Additionally, an enhanced understanding of muscle structure and function in CIDP would
be very helpful to compare to the well-known electrophysiological alterations in the
peripheral nervous system of patients with CIDP 7. To address this, we chose to focus on
the dorsiflexor muscle group, specifically the tibialis anterior (TA), because of its distal
limb location. The TA has important functional roles in gait and balance, and has been
extensively studied in health, disease and aging, to provide comparative data

17,13,18

.

Accordingly, the purpose of the present study was to explore whether MRI is capable of
detecting alterations in muscle quantity and quality relative to strength in those with
CIDP when compared to a matched to a control group.

4.2

Methods

Subjects: Twelve patients (7 men, 5 women) with CIDP (mean age ∼61 years) and ten
age- matched (mean age ∼60 years) control subjects (7 men, 3 women) were recruited to
participate in this study. The local university research ethics board approved the study,
and informed oral and written consent were obtained from both groups prior to testing.
History, clinical, laboratory and electrophysiological features verifying a diagnosis of
CIDP were obtained by an experienced neurologist, with specialty training in
neuromuscular disorders and electrodiagnosis, to exclude other causes of nerve
dysfunction

(i.e.

radiculopathies,

other

polyneuropathies,

or

compressive

mononeuropathies). All patients with CIDP were diagnosed based on the criteria
established by the European Federation of Neurological Societies (EFNS)

19

. Patients

with any metabolic (including diabetes), neurological, or vascular diseases (other than
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related to CIDP) were not included in this study (Table 4.1). Standard measures of
compound muscle action potential amplitudes (CMAP) nerve conduction velocities, and
sensory nerve action potential amplitudes (SNAP) were compared to normative values to
confirm a diagnosis. Furthermore, all patients with CIDP received usual medical care and
responded to treatment with either plasma exchange, intravenous immunoglobulin
(IVIG), or oral prednisone (Table 4.2). All control subjects were healthy, living
independently and medication free. All control subjects were screened by a neurologist to
eliminate any indication of neuromuscular disease.

4.2.1

MRI Measures

The MRI scans of the leg were acquired via serial axial plane scans in a 3.0-Tesla magnet
(Magnetom Spectra 3T mMRBiograph; Siemens Healthcare, Erlangen, Germany). All
MRI scans were completed during a single visit to the magnetic resonance imaging unit.
Both CIDP and control subjects were inserted supine into the magnet feet first with the
TA iso-centered to the bore of the magnet. Inelastic fastenings were used to secure firmly
the legs and feet to the MR table to prevent subtle movements throughout the scanning
procedure. The complete musculature of the left and right legs was imaged from the level
of the tibial plateau to the distal malleoli. MRI for anatomical measures were acquired by
means of a 3D FLASH sequence with the following parameters: 9.57-ms repetition time
(TR); 2.46-ms echo time (TE); 320 x 240 matrix; 243 x 325-mm field of view; 384 slices;
and 0.9mm slice thickness, with slice separation of 1 mm. Total scan acquisition time for
the anatomical scan was approximately 13 min per subject. In a secondary scan during
the same session, T2 relaxation time was determined by means of a spin–echo sequence
with a TR of 3,500 ms. The first spin–echo echo was acquired at TE1 =13.2 ms; the

83

subsequent echoes with 16 equidistant steps had an increment of ΔTE =13.2 ms between
13.2 and 211.2 ms. Other parameters were: slice thickness = 5 mm; matrix = 128 x 128;
field of view = 325 x 325; slices = 30; bandwidth = 601 HZ/Pixel. Total scan acquisition
time for T2 was approximately 12 min per subject.

4.2.2

TA Total Volume, Muscle Composition, and T2 Relaxation
Times

Manual and semi-automated image analysis procedures were used offline to measure
total TA muscle areas, volumes, composition (contractile versus non- contractile muscle
tissue), and T2 relaxation times by means of imaging processing software (OsiriX version
8.2). The researcher was blinded to the group allocation of each subject. Total TA muscle
volume was calculated by manually delineating regions of interest (ROIs) around the
most proximal portion of the TA and at every third slice (2.6 mm) to the most distal slice
comprising distinguishable muscle tissue. Connective tissue, blood vessels, and adipose
tissue were eliminated during the manual tracing of the TA. Subsequently, all ROIs
within the series were saved for further analysis of non-contractile tissue volume. In order
to calculate TA non-contractile tissue volume, an ROI was created, indicative of muscle
tissue only. We used the same method as Moore et al.

10

for non-contractile tissue

volume. T2 relaxation time was calculated for each slice of the TA and a mean T2
relaxation time was calculated for each individual subject. TA ROIs were manually
traced using the same method as described above in the anatomical scans. Pixel-by-pixel
parametric color maps (magma) of T2 relaxation times were created from the signal
intensity of 16 echo images of the TA. The T2 relaxation time was then calculated by
means of the T2FitMap plug- in (version 1.4). The total amount of fat and non-contractile

84

tissue identified was subtracted from the total TA volume to achieve a volume of
contractile tissue only. In addition, this fat corrected volume was used to normalize the
MVC strength (strength per amount of contractile tissue).

4.2.3

Strength Assessment

On a separate appointment that occurred within 1-3 weeks of the MRI tests, voluntary
strength and activation of the dorsiflexors were measured. Subjects were seated in a
custom isometric dorsiflexion dynamometer

20

with the left ankle positioned at 30° of

plantar flexion, while both knee and hip angles were maintained at 90°. Inelastic straps
were wrapped over the dorsum of the foot to secure the foot to the dynamometer.
Movement at the hip was disparaged by securing a padded, C-shaped brace to the distal
aspect of the left thigh. 21,16. Subjects performed three dorsiflexion MVCs, with at least 3
min of rest between each attempt. Subjects were instructed to contract as hard and as fast
as possible to ensure maximal torque, and rate of torque development, was achieved.
Each MVC was held for approximately 3–4 s. Voluntary activation during the 2nd and
3rd MVC attempts was assessed using the interpolated twitch technique

22

. All torque

signals were collected and sampled online at 500 Hz using Spike2 software (Version
7.11; Cambridge Electronic Design, Cambridge, UK) and analyzed off-line to determine
voluntary isometric torques (strength). Compound muscle action potential responses of
the TA were obtained by supramaximal, percutaneous electrical stimulation of the fibular
nerve, distal and posterior to the fibular head. Stimulation was performed through a bar
stimulating electrode using single, 100- us square-wave pulses via a constant-voltage
electrical stimulator (Digitimer stimulator, model DS7AH; Digitimer, Welwyn Garden
City, UK).
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4.2.4

Statistics

Statistical analysis was performed using SPSS software (version 22). Normally
distributed data were analyzed using an independent-samples t-test. The Levene test was
used to determine homogeneity of variance. Non-normal distributions were assessed
using the Shapiro–Wilk test of normality. The T2 relaxation times were not normally
distributed and were assessed using Mann–Whitney non-parametric t-tests. The results
were considered significant at P ≤ 0.05. All data are presented as mean ± standard
deviation.

4.3

Results

There were no significant differences in age, height, weight and BMI between the
patients and control subjects. Participant characteristics are presented in Table 4.1 and
the clinical features of the patients with CIDP are listed in Table 4.2. Despite similar and
equal high levels of voluntary activation (>95%), isometric strength when compared with
controls was significantly lower in the subjects with CIDP (Table 4.3). Patients also had a
lower compound muscle action potential (CMAP) amplitude compared to controls (Table
4.3). When normalized to total muscle volume, patients with CIDP strength was
approximately 29% lower than controls (Table 4.3), and when normalized to fat corrected
contractile tissue volume, CIDP strength was approximately 18% lower compared with
controls. Overall, TA muscle volumes of patients with CIDP were significantly reduced
compared to controls. As a relative percentage of total muscle volume, patients had
significantly less contractile tissue compared with controls (Table 4.3). Consequently,
non-contractile tissue quantities were significantly greater in CIDP when compared with
controls (Table 4.3). Qualitatively, subcutaneous and intramuscular fat was more
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abundant in patients with CIDP when compared with controls (Figure 4.1). Furthermore,
as shown in Figure 4.2, T2 relaxation times were ~39% longer in duration in CIDP versus
controls. Figure 4.3 shows the T2 map of the TA in a patient with CIDP compared with a
control subject.
Table 4.1 Participant characteristics
Anthropometric parameters

Controls (n = 10)

Patients with CIDP (n = 12)

Men/Women

7/3

7/5

Age (years)

59 ± 7.6

60.8 ± 9.1

Height (cm)

167.0 ± 5.0

169.0 ± 8.0

Mass (kg)

71.5 ± 10.3

80.5 ± 10.1

BMI (kg/m2)

26.2 ± 3.1

27.5 ± 4.1

BMI- Body mass index
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Table 4.2 CIDP clinical features
Patient

Duration

MRC

CSF

(M/F,

of

score

protein

prolongation

age)

treatment

(out of 5)

level

/latency

Prednisone



75g/ 3weeks

(y)

M, 77

8

CB

TD

F-Wave

Treatment
IVIG or

(mg/dL)

4/5

330





IVIG

M, 61

22

1/5

150





_

80g/ 4 weeks
IVIG

F, 62

6

4/5

75







20g/ 3 weeks
IVIG

M, 73

6

4/5

60







Plasma
exchange/ 2
weeks, 125 mg
prednisone
daily

M, 47

5

5/5

85





_

55g/ 3 weeks
IVIG

M, 68

3

4/5

70



_

_

20g/ 2weeks
IVIG

M, 45

20

2/5

-







20 mg
prednisone
daily

88

F, 59

10

5/5

290







5mg
prednisone
every other day

M, 60

12

4/5

660







55g/ 4weeks
IVIG

F, 58

12

4/5

96





_

80g/3weeks
IVIG, 10mg
prednisone
daily

F, 59

4

5/5

64



_

_

60g/2 weeks
IVIG

F, 58

9

5/5

125





_

30g/2weeks
IVIG

MRC score of ankle dorsiflexion, CSF- Cerebrospinal fluid; IVIG- Intravenous immunoglobulin, M-Male,
F-Female
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Table 4.3 Strength, electrophysiology, and imaging parameters.

Parameters

Controls

Patients with CIDP

Difference

(n = 10)

(n = 12)

MVC strength (Nm)

42.1 ± 3.2

26.8 ± 3.5*

-36.3 %

TA CMAP Neg PK amplitude

7.1 ± 0.9

4.3 ± 0.8*

-39.4 %

98

95

3%

Total muscle volume (cm3)

117.3 ± 25.2

97.8 ± 17.3*

-17.5 %

Total contractile TA volume (cm3)

110.2 ± 23.5

81.3 ± 15.7*

-26.2 %

Contractile volume (%)

93.2 ± 3.8

84 ± 2.2

-9.8 %

Non-contractile volume (%)

6.8 ± 2.2

16 ± 5.2*

58.2 %

0.38

0.27*

-29.0 %

0.40

0.33*

-17.5 %

(mV)

Voluntary activation (%)

MVC/total muscle volume
(N·m/cm3)
MVC/contractile volume
(N·m/cm3)

MVC- maximum voluntary contraction, CMAP- compound muscle action potential, Neg PK - negative
peak amplitude; N·m- Newton meters. *Significantly different than control (P < 0.05). Values are expressed
as mean ± standard deviation.
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Figure 4.1 MRI cross section of left leg
MRI general anatomic scan: comparison of leg muscles of CIDP (left) vs. control (right) in 2 male
participants. The patient with CIDP is 54 years old and the control subject is 55 years old. The TA muscle
is outlined in green. Note the extensive intramuscular fat infiltration in the patient with CIDP throughout
the leg.

Figure 4.2 T2 relaxation times
T2 relaxation times of the tibialis anterior. *Significantly longer than control (P < 0.05). Values are
expressed as mean ± standard deviation.
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Figure 4.3 T2 maps
T2 maps (ms) of the tibialis anterior muscle: CIDP (left panel) and control (right panel). Purple: muscle
(30–70 ms); orange to yellow: fat (>71 ms); black and blue: connective tissue (<30 ms). T2 maps displayed
here are for the same participants as those depicted in Figure 4.1.

4.4

Discussion

Using two MRI based techniques (T1 and T2 weighted scans) we have revealed
quantitative and qualitative changes in muscle, indicating that compared with control
subjects those with CIDP have structural alterations affecting the contractile capacity of
muscle tissue. The most salient findings from this study are that patients with CIDP had
lower total muscle protein quality and more non-contractile tissue infiltration in the TA,
as indicated both by a greater amount of non-contractile tissue and elongated T2
relaxation times when compared to control subjects. Furthermore, CIDP muscles had
lower normalized strength values than controls when related to corrected muscle
volumes. Absolute dorsiflexion strength of patients with CIDP was ~36% less than the
control subjects. This was not due to differences in voluntary activation of the
dorsiflexors, as both groups produced >95% activation levels. When TA muscle volume
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was expressed relative to strength (normalized strength), the difference between groups
persisted at ~29% lower normalized strength for the CIDP group compared with controls.
This difference denotes a large difference in muscle contractile quality between CIDP
and control subjects indicating that weakness is not simply due to frank loss of tissue.
This is further reinforced by the ~39% longer T2 relaxation times in the CIDP group
when compared with controls. Consequently, beyond validating dorsiflexor muscle
weakness in CIDP, our findings indicate a decrease in protein quality and a loss of total
muscle tissue density in the TA of patients with CIDP. Our findings support and extend
those of Sinclair et al (2012) who found that MTR in the calf muscles was significantly
lower than controls in a group of patients with CIDP 6.
CMAP amplitude, which provides an indication of excitable muscle mass was ~40
percent lower in the CIDP patient group. This finding aligns with our MRI results, which
showed that CIDP patients had a smaller TA volume when compared to controls. Disease
duration did not correlate with the amount of skeletal muscle loss in patients with CIDP.
The muscle weakness in the patients, at the whole-muscle level, could be due to a
quantitative loss of muscle due to denervation or impaired nerve innervation associated
with CIDP, thus allowing replacement of functional muscle tissue with non-contractile
tissues (adipose tissue). Indeed, it has been reported that dorsiflexion muscle weakness
observed in patients with a peripheral neuropathy is correlated with proliferations in
intramuscular adipose tissue, determined from T1-weighted MRI scans

20,23

. This

indication has been further confirmed in our study by longer T2 relaxation times found
for the patients with CIDP when compared to the T2 relaxation times of the control
subjects. T2 relaxation times for healthy human skeletal muscle is reported to be between
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30 and 70ms

24

, and the control subjects in our study showed a mean value of 59ms.

Conversely, the T2 relaxation times of the patients with CIDP were 79ms, which was
significantly longer than the controls. Longer T2 relaxation times are indicative of tissue
that is less dense (lipid in structure) due in part to the slower motion of protons both in
macromolecules as well as water molecules attracted to the surface of the macromolecule
24

.

Heterogeneous expansion of intramuscular non-contractile tissue and fatty infiltration

23

may not only reduce total muscle mass, but also could disrupt normal fascicular
organization. Consequently, unfavorable changes in muscle tissue composition are likely
key structural alterations that contribute to muscle weakness in CIDP. Findings from
other MRI studies that assessed cross sectional area of peripheral nerves including L5 and
cauda equina diameter, indicate that innervated muscle tissue would be affected 2. Our
findings are also supported by a study that found muscle disruptions in Charcot-MarieTooth neuropathy

25

and in another that showed declines in skeletal muscle function in

patients with diabetic peripheral neuropathy

26

. Thus, reductions in muscle quantity and

quality are likely driven by CIDP-related neural factors, such as motor axon loss

7

and

impaired neural signaling perhaps related to nerve lesions as reported in prior studies that
presumably lead to accelerated muscle atrophy 3.
Importantly, we found that patients with CIDP were weaker relative to volume of muscle
even when compared using fat corrected muscle volumes (normalized force). This
indicates that the intrinsic force generating capacity of the presumed viable muscle tissue
is lower in those with CIDP than controls supporting the concept that disruptions in
neural innervation and function affect muscle tissue. We showed previously that patients
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with CIDP have impaired neuromuscular stability (higher jitter and jiggle) and percent
blocking compared to controls 7. These nerve alterations therefore could lead to
diminishments in muscle strength even when corrected for non-contractile tissue.
Although motor unit or axon loss is a feature of CIDP 7 it is not known whether there is a
preferential loss of for example Type II fibers and via collateral reinnervation of
remaining Type I fibers found in ageing

26

and other neuropathies contributing to

morphological changes within the muscle. Ultimately, due to a poorer quality of
reinnervation, these muscle fibers may have intrinsic strength decrements as
demonstrated in the present study by lower contractile force per cross sectional area
(volume) 27,28.
In using MRI sequences, T2 and the general anatomical scans, important insights have
been gained into fundamental changes of skeletal muscle in patients with CIDP.
Dorsiflexor weakness in CIDP is likely an outcome of numerous factors, including, but
not limited to motor unit loss and accompanying muscle denervation and atrophy.
Impaired neural signaling due to the primary site of lesions of the peripheral nerves also
may indirectly contribute to poorer muscle tissue quality as reflected by lower normalized
force compared with controls. Accordingly, T2 and the general anatomical scans can
offer additional understanding into pathological and morphological disruptions to wholemuscle tissue composition that may contribute to diminished muscle function in CIDP.
These results further support the utilization of MRI as a tool for muscle analysis and
provide a better understanding of the impact of neuronal changes in CIDP on muscular
characteristics. Finally, this information may be essential in targeting and evaluating
treatment modalities in patients with CIDP.
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Chapter 5

5

1

Nerve Dysfunction Leads To Muscle Morphological
Abnormalities In Chronic Inflammatory Demyelinating
Polyneuropathy Assessed By MRI
5.1

Introduction

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease
characterized primarily by demyelination and secondary axonal degeneration of
peripheral nerves. Patients typically present with symmetrical motor deficits such as
diffuse muscle weakness, as well as sensory impairments. Focal alterations in the
lamellar pattern of myelin, which lead to segmental demyelination, are present in CIDP.
The myelin sheath becomes discontinuous which has repercussions in relation to axonal
conductance 1. Studies related to neuromuscular function have mainly focused on the
neuropathic aspects of CIDP and their involvement in motor impairment. However,
changes in skeletal muscle quality and quantity maybe a consequence of motor nerve
deficits, but these aspects have not been investigated extensively

2,3

. Nerve lesions in

CIDP have been shown by magnetic resonance imaging in the lumbar nerve roots (L4
and L5), tibial nerve, and brachial plexus

4,5

. To date, the effect of nerve lesions in

patients with CIDP has not been comprehensively explored in relation to quality and
quantity of skeletal muscle. Only a few studies have describe dissociations between
A version of this chapter has been published. Used with permission from John Wiley and Sons, Inc.
1

Gilmore K.J, Fanous J, Doherty, T.J., Kimpinski, K., Rice, C.L. Nerve Dysfunction Leads To Muscle

Morphological Abnormalities In Chronic Inflammatory Demyelinating Poloyneuropathy Assessed By MRI
Clinical Anatomy. 33 1 77-84 (2020).
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MRI detected nerve impairments and clinical findings of decrements in muscle strength
6,7

. T2-weighted MRI and general anatomical MRI (T1) are advantageous beyond

providing an overall assessment of muscle mass that can be used for example to
normalize strength measures, as they also provide a complementary understanding of
tissue density and muscle protein structural integrity

8,9

. Thus, muscle weakness in

patients with CIDP may be related to reductions in both quantity and quality of skeletal
muscle, however only one study has investigated muscle morphology in patients with
CIDP 10.
A previous study from our group found that overall tibialis anterior (TA) muscle volumes
were lower in patients with CIDP compared with age and sex matched controls, and
dorsiflexion strength was approximately 29% lower in the CIDP group

10

. Furthermore,

non-contractile tissue quantities were roughly 60% greater in the TA muscle of patients
when compared with controls. Thus, when strength was normalized to fat corrected
contractile tissue volume, strength remained lower by approximately 18% in patients with
CIDP compared with controls 10. Although the dorsiflexors have functional importance in
gait and balance, it remains to be determined whether these findings are unique to this
muscle group for anatomical and functional reasons or whether other muscles of the leg
would be affected similarly. Moreover, because CIDP affects distal musculature more
severely

11

we investigated the triceps surae, including the soleus, medial head of

gastrocnemius (MG), and lateral head of gastrocnemius (LG). Indeed, the triceps surae
has important functional roles in gait and balance, and has been extensively studied in
health and aging, to provide comparative data 12,13,14.
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Histochemical studies have shown that the TA contains 70–75% type II fibers

15

and

similarly the soleus, is rather homogeneous, being composed of 80% type I muscle fibers
14,15

. However, unlike the TA, the soleus muscle has been shown to be spared from age-

related muscle atrophy, contractile slowing, and a loss of motor units when compared to
the TA

16

. Furthermore, when the soleus is compared with the gastrocnemii, which are

composed of about 50% slow twitch (ST) fibers, the gastrocnemii show substantial
anatomical loss when older individuals are compared with younger adults 17. Thus, there
may be anatomical or functional features among different muscles despite sharing the
same spinal nerve root innervation that could be affected differently by the demyelination
process of peripheral nerves. Given these deficiencies in the literature, a more
comprehensive understanding of muscle structure and function from various muscle
groups

in

CIDP

would

be

advantageous

in

addition

to

the

well-known

electrophysiological and anatomical alterations in the demyelinated peripheral nerves of
CIDP patients 10. Accordingly, the purpose of the present study was to explore the large
muscles of the posterior leg compartment to examine the degree to which plantar flexion
strength and muscle quantity and quality are affected in those with CIDP when compared
to matched controls. It was hypothesized that demyelinated peripheral nerves would lead
to uniform reduction in all portions of the triceps surae in both quantity and quality of
muscle of patients with CIDP.

5.2

Methods

Ten patients (six men, four women) with CIDP (mean age 62 years) and nine agematched (mean age 60 years) control subjects (five men, four women) participated in this
study (Table 5.1). The local university research ethics board approved the study, and both
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groups provided informed oral and written consent prior to testing. A clinical history, as
well as laboratory and electrophysiological descriptions verifying a CIDP diagnosis were
obtained by an experienced neurologist, with specialty training in electrodiagnosis and
neuromuscular disorders. All other causes of nerve dysfunction (i.e.,radiculopathies,
other polyneuropathies, or compressive mononeuropathies) as well patients with any
metabolic (including diabetes), neurological, or vascular diseases (other than related to
CIDP) were screened and these subjects were not included in this study. All patients were
diagnosed based on the criteria established by the European Federation of Neurological
Societies

11

(Table 5.2). Standard measures of nerve conduction velocities, compound

muscle action potential amplitudes (CMAP) (Table 5.1) and sensory nerve action
potential amplitudes (SNAP) were compared to normative values to establish a CIDP
diagnosis. Furthermore, all patients with CIDP were receiving usual medical care and
responded to treatment with intravenous immunoglobulin (IVIG), oral prednisone, or
plasma exchange (Table 5.2). All control subjects were healthy, medication free, living
independently and were screened by the same neurologist to eliminate any indication of
neuromuscular or metabolic disease.

5.2.1

Strength Assessment

Within the same week as the MRI scans were acquired, voluntary strength of the right
plantar flexors was measured. For strength assessments, subjects were seated in a plantar
flexion isometric dynamometer with the right ankle positioned at 90°of plantar flexion
and both knee and hip angles were maintained at 90°18. Movement at the hip was
minimized by fixing a thinly padded, C-shaped sup-port over the distal aspect of the right
thigh. 10,19. Two Velcro straps attached to the dynamometer footplate were secured across
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the dorsum of the foot and the toes to secure the foot to the dynamometer footplate.
Control subjects performed three plantar flexion maximum voluntary isometric
contractions (MVCs), with 3–5 min of rest between each contraction. Patients with CIDP
required three to five maximal isometric contractions, with two or more contractions of
the contractions within 5% of each other. To mitigate fatigue in the group 5 min of rest
was given between each maximal contraction. Both groups were given strong verbal
encouragement and torque visual feedback. Each MVC was held for approximately three
to four seconds. MVC torque was calculated as the highest torque value achieved from
any of the three attempts. All torque signals were collected and sampled online at 500 Hz
using Spike2 software (Version 7.11; Cam-bridge Electronic Design, Cambridge, UK)
and analyzed offline to determine voluntary isometric torques (strength).

5.2.2

MRI Measures

All MRI scans were completed during a single visit to the MRI unit. Scans of the triceps
surae were acquired via serial axial plane images in a 3.0-Tesla magnet (Magnetom
Spectra 3T mMRBiograph; Siemens Healthcare, Erlangen, Germany). Control and CIDP
subjects were inserted supine into the magnet, feet first with the triceps surae iso-centered
to the bore of the magnet. Inelastic fasteners were used to secure tightly the legs and feet
to the MR table to avoid subtle movements during the scanning process. The complete
musculature of the left and right legs was imaged from the distal malleoli to the proximal
tibial plateau. MRI for anatomical measures (T1) were acquired by means of a 3D
FLASH sequence with the following parameters: 9.57-ms repetition time (TR); 2.46-ms
echo time (TE); 320×240 matrix; 243×325-mm field of view; 384 slices; and 0.9 mm
slice thickness, with slice separation of 1 mm. Total scan acquisition time for the
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anatomical scan was approximately 13 min per subject. A secondary scan during the
same session was performed to determine T2 relaxation times by means of a spin–echo
sequence with a TR of 3,500 ms. The first spin–echo was acquired at TE =13.2 ms; the
subsequent echoes with 16 equal distant steps had an increment of ΔTE =13.2 ms
between 13.2 and 211.2 ms. Other parameters were: slice thickness = 5 mm; matrix =
128×128; field of view = 325×325; slices = 30; bandwidth = 601 Hz/pixel. Total T2 scan
acquisition time was approximately 12 min per subject.

5.2.3

Triceps Surae Total Volume, Muscle Composition, and T2
Relaxation Times

Before calculating MRI results, an inter- rater reliability test was completed to evaluate
the reliability of two experimenters calculating muscle mass and subsequently
quantifying contractile versus non-contractile tissues in the triceps surae complex. The
results of this test indicated that both evaluators were within 95% confidence with each
other. Manual and semi-automated image analysis procedures were used offline to
measure the soleus, medial and lateral gastrocnemii muscle areas, volumes, composition
(contractile versus non contractile muscle tissue), and T2 relaxation times by imaging
processing software (OsiriX version 8.3). The researcher was single blinded to group
allocation. Total soleus, medial and lateral heads of gastrocnemius muscle volumes were
calculated by independently manually delineating regions of interest (ROIs) around the
most proximal portion of each muscle and at every third consecutive slice (2.6 mm) to the
most distal slice containing distinguishable muscle tissue. Connective tissue, adipose
tissue and blood vessels were eliminated during the manual tracing of each of the three
triceps surae muscles. All ROIs within the same muscle series were saved for further
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analysis and calculation of non-contractile tissue volumes. In order to calculate noncontractile tissue volumes for all three muscles an ROI was created, indicative of only
muscle tissue

20

. T2 relaxation time was calculated for each slice of the soleus, medial

and lateral heads of gastrocnemius and a mean T2 relaxation time was calculated for each
subject. The soleus, medial and lateral heads of gastrocnemius muscle ROIs were
manually traced using the same method as described above in the (T1) anatomical scans.
Pixel-by-pixel parametric color maps (magma) of T2 relaxation times were created from
the signal intensity of 16 echo images of the three muscles. The T2 relaxation time was
then calculated by means of the T2 Fit Map plug-in (version 1.5). The total amount of fat
and non-contractile tissue identified was subtracted from the total volume of each muscle
compartment to achieve a volume of contractile tissue only. In addition, this fat corrected
volume was used to normalize the MVC strength (strength per amount of contractile
tissue).

5.2.4

Statistics

Statistical analysis was performed using SPSS software (version 22). Normally
distributed data were analyzed using an independent-samples t-test. The Levene test was
used to determine homogeneity of variance. Non-normal distributions were assessed
using the Shapiro–Wilk test of normality. The T2 relaxation times that were not normally
distributed were assessed using Mann–Whitney non-parametric t-tests. Cohen’s D effect
sizes were calculated for group differences. The results were considered significant at
P≤0.05. All data are presented as mean and standard deviation.
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5.3

Results

There were no significant differences in age, height and weight between the patients with
CIDP and control subjects. Participant characteristics are presented in Table 5.1 and the
clinical features of the patients are listed in Table 5.2. Isometric plantar flexion strength
was 28% lower in patients with CIDP when compared with controls (Table 5.1).
Electrophysiological findings also indicated axonal dysfunction with patients having 50%
lower CMAP amplitude of the tibial nerve compared to controls (Table 5.1). The total
triceps surae volume of patients with CIDP was significantly lower by 19.3% compared
to healthy controls. When eliminating the fat and other non-contractile tissue within the
total volume of the triceps surae, the patients with CIDP had 47.5% less contractile tissue
(Figure 5.1). Consequently, non-contractile tissue quantities were significantly greater
(82%) in CIDP when compared with controls (Figure 5.2). Qualitatively, subcutaneous
fat was more abundant in patients with CIDP when compared with controls. When
normalized to total triceps surae muscle volume, strength was approximately 17% lower
in CIDP than controls (Table 5.1) and when normalized to fat corrected contractile tissue
volume, CIDP strength was approximately 30% lower compared with controls.
Furthermore, as shown in Figure 5.3, T2 relaxation times in the soleus, medial and lateral
heads of gastrocnemius were 36.8%, 37.3% and 26.0% longer induration (although not
statistically significant) in CIDP versus controls. Figure 5.4 shows cross-sectional T1weighted MRI scan comparing leg musculature of control versus CIDP with the soleus
(SL), MG and LG outlined. Figure 5.5 shows the T2 map of the triceps surae (SL in blue,
MG in orange, and LG in yellow) in a control subject compared to a patient with CIDP.
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Table 5.1 Participant characteristics
Subject characteristics

Controls (n = 9)

Patients with CIDP (n = 10)

Men/Women

5/4

6/4

Age (years)

59 ± 6.2

61.8 ± 8.2

Height (cm)

167.0 ± 3.0

169.0 ± 8.0

Mass (kg)

73.5 ± 9.4

80.5 ± 8.4

MVC strength (Nm)

132.7 ± 12.2

95.3 ± 8.8*

Normalized strength to total triceps

0.24 ± 0.03

0.15 ± 0.01*

7.5 ± 0.34

3.7 ± 0.72*

surae volume (Nm/cm3)

CMAP (mV)

MVC - maximum voluntary contraction; CMAP - compound muscle action potential of tibial nerve. There
were only significant differences (P< 0.05) in strength. Normalized strength is expressed as fat corrected
triceps surae volume. Values are expressed as means ± standard deviations.
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Table 5.2 CIDP clinical classification
Patient

M, 77

Duration

MRC

CSF level

of CIDP

score

(y)

8

CB

F-Wave

Response to

(g/L

prolongation

IVIG or

(out of 5)

isolation)

/latency

Prednisone

3/5

3.3



75g/ 3weeks



TD



IVIG

M, 61

22

1/5

1.5





-

80g/ 4 weeks
IVIG

F, 62

6

4/5

0.75







20g/ 3 weeks
IVIG

M, 73

6

4/5

0.6







Plasma
exchange/ 2
weeks, 125 mg
prednisone daily

F, 60

7

4/5

0.75





-

45g/ 3 weeks
IVIG

M, 63

3

4/5

0.7



-

-

20g/ 2weeks
IVIG

M, 45

20

2/5

-







20 mg
prednisone daily

F, 59

10

5/5

2.9







5mg prednisone
every other day
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M, 60

12

4/5



6.6





55g/ 4weeks
IVIG

F, 58

12

4/5



0.96





80g/3weeks
IVIG, 10mg
prednisone daily

CSF- Cerebral spinal fluid; IVIG- Intravenous immunoglobulin; - represents no value;  - value observed;
CB-Conduction block; TD - Temporal dispersion, M-Male, F-Female
500

*

450
400

Volume (cm3)

350
300

*

250
200
150
100
50
0

Soleus

MG

LG

Total Volumes Control

Figure 5.1 Total muscle volume of triceps surae
Total muscle volumes of the soleus, medial head of gastrocnemius (MG), and lateral head of gastrocnemius
(LG). *P < 0.05, significantly different than controls. Values are expressed as means ± standard deviations.
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CIDP

Figure 5.2 Total contractile volume triceps surae
Total triceps surae contractile volumes of the soleus, medial head of gastrocnemius (MG), and lateral head
of gastrocnemius (LG). *P < 0.05, significantly different than controls. Values are expressed as means ±
standard deviations.
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140

*
T2 Relaxation time (ms)

120

*
*

100

80
60

40
20
0

Soleus
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Control
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CIDP

Figure 5.3 T2 relaxation times of triceps surae
T2 relaxation times of the soleus, medial head of gastrocnemius (MG), and lateral head of gastrocnemius
(LG). *P < 0.05, significantly longer than controls. Values are expressed as means ± standard deviations.
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Figure 5.4 MRI T1 cross section of triceps surae
Cross-sectional T1-weighted MRI scan: comparing leg musculature of control (left) vs. CIDP (right).
Soleus (SL), medial head of gastrocnemius (MG) and lateral head of gastrocnemius (LG) are outlined. Note
the prominent marbleized appearance of the leg muscles of the patient with CIDP due to extensive
intramuscular fat infiltration.

Figure 5.5 MRI T2 cross section of triceps surae
T2 maps (ms) of the soleus (SL), medial head of gastrocnemius (MG), and lateral head of gastrocnemius
(LG) muscles: control (left panel) vs. CIDP (right panel). Muscle: purple, blue (30-70ms); fat green, yellow
(>71 ms); connective tissue: black, purple (<30 ms). T2 ranges values from 21. T2 maps displayed here are
from the same participants shown in Figure 5.4.
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5.4

Discussion

The present study aimed to establish the degree to which the posterior leg compartment,
specifically the triceps surae is affected by the demyelinating nerve disease CIDP.
Utilizing two MRI techniques, (T1 andT2-weighted scans), we discovered quantitative
structural alterations in all portions of the triceps surae, demonstrating that patients with
CIDP have significant atrophy and no contractile tissue infiltration that severely affect the
contractile capacity of skeletal muscle tissue. Absolute plantar flexion strength of patients
was roughly 28% less than the control subjects and when triceps surae muscle volume
was expressed relative to strength (normalized strength), the difference between groups
persisted with roughly 30% lower normalized strength for the CIDP group when
compared to controls. The persistence of the strength difference is indicative of the lower
muscle contractile quality in CIDP, which is further supported by the roughly 35% longer
T2 relaxation times in all three muscles of CIDP individuals compared with controls.
Thus, muscle weakness in patients with CIDP cannot be due to a loss of muscle tissue
alone. Furthermore, disease duration was not related to the amount of skeletal muscle
mass present in patients. Electrophysiological outcomes also indicated more prominent
abnormalities that were suggestive of axonal dysfunction (e.g., CMAP amplitude) in the
lower extremity. T2 relaxometry and water-fat separation techniques were not used in
this study, thus we are notable to quantify total fat infiltration separated from water
content or other non-contracting substances. The most important conclusions from this
study are that patients with CIDP had significantly less total muscle volume indicated by
T1 scans, as well lower total muscle protein quality as reflected by longer T2 relaxation
times, and greater no contractile tissue infiltration found equally in the soleus, medial and
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lateral heads of gastrocnemius and supported by longer T2 relaxation times when
compared to control subjects. It is important to draw attention to the two possible
contributing mechanisms at play in the patients. Not only are these patients
disadvantaged by chronic nerve demyelination, but also the process of aging may
compound these effects. Several studies using MRI techniques that have compared ageassociated differences in muscle composition have shown that various muscles within the
leg are affected to different degrees by aging. One study demonstrated that triceps surae
muscle volume could be reliably calculated using maximal anatomical cross-sectional
area values from MRI scans

22

. A subsequent study investigated changes in the

architecture of the triceps surae muscle architecture in a group of young men (25.3 ± 4.5)
and a group of old men (73.8 ± 4.4). Additionally, that study reported that the triceps
surae in the old group was smaller in volume in all individuals compared with the young
17

. Our mean values for the control subjects fit closely with the volumes presented by this

group. Furthermore, a study showed age-associated reductions in contractile tissue and
subsequent increases in adipose and connective tissue composition using MRI in the
triceps surae. These results further support our control group findings regarding force as
well as muscle volume. In the older cohort, in addition to 39% lower isometric plantar
flexion strength, total triceps surae volume was smaller by 17.5%, whereas the relative
amounts of triceps surae intramuscular adipose tissue and gastrocnemii intramuscular
connective tissue were larger by 55.1%and 48.9%, respectively 23.
A study by Dalton et al (2009) supports that not all skeletal muscles are affected equally
by the aging process and that the soleus in relation to both heads of the gastrocnemius
may possess some type of neural protection as it was preserved to a greater degree in
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aged individuals

24

. Indeed, it has been shown that sarcopenia is much more apparent in

the LG and MG compared with soleus

17

. Heterogeneous increases of intramuscular

adipose and non-contractile connective tissue may not only diminish total triceps surae
muscle mass, but also could alter the usual fascicular fibre organization 25. This may help
explain the lower specific tension we found for this muscle group. Consequently,
negative changes in skeletal muscle tissue amount and relative composition of contractile
verses no contractile tissue lead to important structural modifications that contribute to
plantar flexion muscle weakness in patients with CIDP. Thus, although disuse and agerelated factors may play a role in the observed differences, it is likely that the primary
cause is axonal dysfunction. In the past decade, numerous abnormal MRI findings in
nerves of patients with CIDP have been reported.
Several studies have discovered abnormal hypertrophy of both ventral and dorsal spinal
nerve roots in CIDP
syndrome

32,33

26,27,28,29,30,31

which has also been demonstrated in Guillain–Barre

. Hypertrophy of spinal nerve roots has frequently been described in

combination with abnormal nerve enhancement

34,35,36

. Increased signal intensity on T2-

weighted images in the brachial plexus or nerve trunks has also been observed in some
CIDP MRI studies

37,38,39

. Although nerve root enlargement is not specific for CIDP,

several studies have demonstrated the frequencies of these abnormalities that are detected
by MRI. For example, Midroni et al (1999) reported enhancement of the cauda equina in
(69%) of patients with CIDP

28

and Duggins et al (1999) reported detection of cervical

nerve root hypertrophy in (57%) of patients with CIDP 27. Although these structural nerve
abnormalities are apparent, few studies have explored the effect on skeletal muscles. In a
few related studies, our findings are supported by one that found muscle disruptions in
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Charcot–Marie-Tooth neuropathy

40

and some that have shown declines in skeletal

muscle quantity and quality in patients with diabetic peripheral neuropathy

17, 41

. Thus,

reductions in muscle quantity and quality are likely driven by CIDP-related neural
factors, such as motor axon loss 10 and impaired neural signalling perhaps related to nerve
lesions or segmental demyelination as reported in prior studies that presumably lead to
accelerated muscle atrophy 4.
Moreover, studies have shown proximal demyelination results in enlarged brachial and
lumbar plexuses as well as enlargements in the cauda equina demonstrating segmental
demyelination in nerves that have proximal roots. Findings from this study in
combination with our previous results

10

indicate that both anterior and posterior leg

compartments are affected to the same extent in CIDP. There does not seem to be any
difference in muscle morphology specifically quantity and quality of skeletal muscle in
the TA or within the constituent muscles of the triceps surae of patients with CIDP, and
indeed muscles of the two major leg compartments seem to be equally affected. Thus,
likely both the deep peroneal nerve as well as the tibial nerve has been affected to the
same degree by the demyelinating process and subsequently the distal muscles have been
compromised. This indicates that the insult to the nerve is more proximal possibly at its
origin of the sciatic nerve and supports the finding of sacral plexus root enlargement
reported previously 35.
We were surprised by our initial findings in the TA muscle, which prompted us to
explore whether another critical gait muscular group was affected by CIDP. In addition,
the fiber type compositions of the main portions of the triceps surae are quite different
and it was important to assess whether the soleus might be differently affected than the
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gastrocnemeii with support from studies on age-related changes as outlined above.
Furthermore, a major concern for patients with CIDP is ambulation, and quantifying how
several key leg muscles involved in gait are affected by a chronic nerve demyelination is
very pertinent to the well being and quality of life of those with CIDP. Our results are
further supported by Ohyama et al (2017) who, using computed tomography, showed
significant atrophy to be more pronounced in the distal musculature compared to
proximal muscles of patients with CIDP

42

. Thus, morphological alterations to distal

skeletal muscle in patients seem to be uniform regardless of anatomical location or
functional requirements. Furthermore, compositional changes within the muscle
compartments, specifically infiltration by fat and connective tissue, may disrupt muscle
architecture further diminishing effective functional capacity.
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Chapter 6

6

General Discussion and Summary
6.1

General Discussion

This thesis provides considerable unique experimental evidence concerning the
consequences of chronic inflammatory demyelinating polyneuropathy (CIDP) on the
human neuromuscular system. The first half of this thesis concentrated on the motor axon
changes that accompany CIDP. The results in this body of work indicate that patients
with CIDP have a loss of motor units, neuromuscular transmission instability, abnormal
firing rates of individual motor units and neuromuscular conduction block (Chapters 2,
3). The second half of this thesis focused on how these alterations to the motor axon and
abnormal neuromuscular transmission behavior affect skeletal muscle mass and
composition. The findings of the later chapters indicate that CIDP related motor unit loss,
block and instability is associated with skeletal muscle atrophy as well as increased noncontractile intramuscular tissue infiltration (Chapter 4). Furthermore Chapter 4 elucidates
an important finding that patients with CIDP are weaker when normalized to fatcorrected muscle volumes in the TA muscle of the anterior compartment that can be
related to findings from the first two studies. This indicates there are intrinsic structural
abnormalities within the contractile protein apparatus of the muscle fibers. The final
Chapter (5) of this thesis investigates whether these distal symmetrical axonal losses and
instability have homogeneous effects on the muscle tissue innervated. This was
accomplished by using MRI to explore the portions of the triceps surae muscle group of
the posterior compartment of the leg in patients with CIDP. Results show that regardless
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of distal nerve loss and dysfunction, associated muscle undergoes uniform changes of
atrophy and non-contractile tissue infiltration in all muscles regardless of functional
differences or anatomical location. Combined, these findings provide a more
comprehensive understanding of the current understanding of how CIDP affects the
neuromuscular system as well mechanisms behind the functional limitations seen in
patients with CIDP.
Although not well understood, there is a consensus that CIDP related demyelination
causes neuromuscular dysfunction, and it has been presumed that part of this dysfunction
is due to neuromuscular conduction block and the loss of motor axons

1,2,3

. However,

studies to date have not quantified the losses of motor units or stability parameters
associated with demyelinated motor axons in patients with CIDP. In this thesis, the
results in Chapter 2 confirmed the suspected concept of motor unit loss by exhibiting
reduced MUNEs in the tibialis anterior (TA) of patients with CIDP versus healthy control
subjects. This finding is important as it confirms that chronic motor axon demyelination
to proximal nerve roots and plexuses can impact motor unit number and function in a
distal muscle 4. Chapter 2 also builds on this characterization by demonstrating increased
neuromuscular jitter and jiggle in patients relative to controls, which reflects pathological
alterations in neuromuscular action potential propagation or neuromuscular junction
transmission instability. Importantly this Chapter demonstrates the utility of concentric
needle derived DQEMG for the detection of motor unit loss and differences in
neuromuscular transmission fidelity when comparing patients with CIDP to healthy
controls. Furthermore, this Chapter highlights the significance of DQEMG as a valuable
methodology that is sensitive to changes not currently detectable in standard clinical
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nerve conduction studies. Finally, the neuromuscular stability outcomes of Chapter 2
indicate that jitter and jiggle are valuable indices for classifying axonal alterations in the
early stages of disease, preceding the loss of motor units or the onset of muscle atrophy.
Chapter 3 of this thesis builds upon previous findings of axonal transmission failure via
single fiber motor unit experimentation 2. Numerous animal model studies using
experimental autoimmune neuritis (CIDP equivalent in rodents) have demonstrated
transmission disturbances in motor axons, neuromuscular junctions, and single muscle
fibers, all of which culminate into failed action potential propagation in motor nerves or
skeletal muscle fibers 5. Surprisingly, patients with CIDP demonstrated abnormally high
firing rates of early recruited low-threshold motor units at low volitional contraction
intensities. These high firing rates observed in small, early recruited motor units may
reflect a compensatory strategy to mitigate the overall motor unit loss. Findings from
Chapter 3 also indicate that CIDP related demyelination, blockage and axon loss might be
more prominent in larger, later recruited motor units. The surviving smaller type I motor
units must discharge at faster rates to produce the necessary force in the absence or
blockage of faster later recruited type II motor units. The finding of conduction failure (in
the form of diminished motor unit firing rates or complete block) supports the concept
that transmission failure occurs in human patients with CIDP. Moreover, this
susceptibility of motor units to demonstrate transmission failure and abnormal firing rates
could have functional implications, specifically regarding quantity and quality of the
muscle tissue innervated by unhealthy nerves.
Indeed, MR imaging in the lumbar nerve roots and tibial nerve has shown nerve lesions
in patients with CIDP

6,7

. The loss of strength in muscles of those with CIDP is most

127

severe distally, can be profound and likely has a direct significance on functional
impairments. However, very little data exist regarding the morphological characteristics
of the limb musculature in patients with CIDP, specifically muscle quantity and quality.
In Chapters 4 and 5 of this thesis, two MRI based techniques (T1 and T2 weighted scans)
are utilized to reveal CIDP related quantitative and qualitative changes in skeletal
musculature. Results of Chapter 4 indicated that compared to control subjects those with
CIDP have structural alterations that ultimately affect the contractile capacity of muscle
tissue. The most important findings from Chapter 4 are that patients with CIDP have
lower total muscle protein quality and more non-contractile tissue infiltration in the TA,
as indicated both by a greater amount of non-contractile tissue and elongated T2
relaxation times, compared to healthy controls. This Chapter also demonstrates an
interesting finding that patients with CIDP are weaker relative to volume of muscle even
when compared using fat corrected muscle volumes normalized to force. This is
significant because it indicates that patients with CIDP have disruptions to the intrinsic
structural integrity at the molecular level of muscle proteins, supporting the concept that
disruptions in neural innervation and function affect muscle protein quality.
Consequently, these unfavorable changes to muscle tissue composition are likely key
structural alterations that contribute to functional weakness in patients with CIDP.
Chapter 5 investigates the homogeneity of the effects of chronic demyelination in a
separate leg compartment Findings from Chapter 5 in combination with results from
Chapter 4 indicate that both anterior and posterior leg compartments are affected to the
same extent in CIDP. There does not appear to be any difference in muscle morphology
specifically quantity and quality of muscle tissue in the TA or within the constituent
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muscles of the triceps surae in patients with CIDP. Findings from these two Chapters
indicate that muscles of the two major leg compartments seem to be equally affected by
the disease process. Thus, likely both the deep peroneal nerve as well the tibial nerve
have been affected to the same gradation by the demyelinating process and subsequently
the distal muscles have been compromised. This indicates that the focal insult to
peripheral nerves is more proximal possibly at their origin of the sciatic nerve and
supports the findings of sacral plexus root enlargement that has been previously reported
6,7

. In summary, the studies presented have elucidated many neuromuscular deficits in

patients with CIDP and this information may be essential in disease management as well
in directing and assessing treatment modalities.

6.2

Limitations

The first half of this dissertation uses EMG techniques that are not without limitations.
The characteristics of an EMG signal are largely affected by the level of voluntary
contraction, the anatomical and physiological properties of the muscle, the physical
characteristics of the electrode used to detect the signal as well as the position of this
electrode relative to the active muscle fibres. A specific limitation related to MUNE
consists of the challenge in maintaining concentric needle electrode positioning during
intramuscular recordings. Although the DQEMG software provides visual feedback and
cueing, inconsistent needle electrode positioning may affect the sizes of detected action
potentials recorded from active motor units. Intramuscular concentric needle depth has
also been shown to have a significant effect on MUNE calculation 8. Potential bias
regarding depth and location of needle electrode intramuscular insertion was taken into
account through careful needle manipulation or different insertion sites so that the
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detection of motor units was representative of the population of motor units within the
muscle.
There is clear evidence suggesting that that the level of force can have a significant
impact on the sizes of both needle and surface detected motor unit action potentials
sampled using DQEMG. The amplitude of the needle and surface detected motor unit
action potentials increase as the level of force increases. Coupled with this change in
action potential size is an increase in motor unit firing rate as well as a decrease in the
magnitude of the MUNE values at higher force levels 9. In order for DQEMG to maintain
its accuracy and usefulness, methods of controlling for the level of force must be efficient
and applicable to the study design. In order to reduce force variability the studies in this
body of work used a consistent measure of torque and root-mean square EMG during
signal acquisition to provide an indication of the absolute or relative level of force or
muscle activation.
Motor unit number estimations and stability measures were conducted in the right leg
(Chapters 2 and 3) and in the study calculating muscle quality and quantity the left leg
(Chapter 4) was analyzed. This was done knowing that motor unit pathology is
symmetrical in patients with CIDP 4. This means that motor unit losses measured and
detected in one side of the body should reflect losses in the opposite side to a similar
degree. The left side was the non-dominate limb in 95% of all patients and controls tested
and although not significant both plantar flexion and dorsiflexion strengths were slightly
weaker in the non-dominate limbs of patients with CIDP. Additionally, the patient group
studied throughout this thesis featured a more severe neuropathy, with a more extreme
motor involvement than what would be expected in patients in the early stages of the
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10,11,12

disease

.

Loss of cells from the motor system occurs during the normal aging process, leading to
reduction in the complement of motor neurons and muscle fibers. This latter age-related
decrease in muscle mass is termed sarcopenia and is often exacerbated with the
detrimental effects of a sedentary lifestyle in older adults, leading to a significant
reduction in the overall reserve capacity of the neuromuscular system

13, 14, 15 16

. The

cellular processes that lead to age-related loss of spinal motor neurons in healthy adults
are not well understood but it is widely agreed that nerve cell death is the precursor for
the numerous neuromuscular adaptations seen with normal adult aging. These detrimental
effects to the neuromuscular system manifest and are detectable by the six or seventh
decade of life

17

. The mean ages of the patients and control subjects in this thesis were

approximately 60 years old. Therefore it is reasonable to expect that the majority of
patients with CIDP would not only be expressing CIDP related neuronal changes but also
age-related changes to neurons. Thus, it was important to have age-matched controls.
This may affect the generalizability of the results found in this thesis. Patients with CIDP
may be differentially affected as they age, compared to how CIDP may influence a group
of disease free younger adults.
Lastly, the patient and control experimental groups included a comparable number of
males and females. The two groups were sex matched, however due to the rarity of the
disease a sample size of 10-12 subjects was studied which did not provide enough
statistical power to formally compare sex-based differences in CIDP.
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6.3

Future Directions

The studies contained within this thesis provide a foundation from which further
investigation can build upon. To further elucidate, quantify and expand the findings of
Chapter 2, with a study investigating the loss of motor units in a more proximal muscle
would be of value. CIDP has demonstrated detrimental affects to distal human
musculature, however it is not known whether similar demyelinating effects are expected
in proximal muscles of the body.

Due to the length dependent nature of the disease it

would be interesting to know if proximal muscles are preserved to a greater or lesser
degree than distal muscles.
Quantification of isotonic muscle power generation, force-velocity relationship and
maximal contractile velocity might considerably complement the understanding of
Chapters 3, 4 and 5 regarding how CIDP impacts muscle function. Indeed, there is good
evidence that voluntary isotonic (concentric and eccentric) contractions have different
motor unit firing rates than voluntary isometric contractions

18,19

. Therefore,

intramuscular fine wire recordings could be collected during dynamic contractions in a
distal muscle to assess the firing characteristics of individual motor units during a
dynamic task. To complement Chapter 3 repetitive nerve stimulation at different
frequencies could also be used to test for neuromuscular transmission failure in order to
quantify whether and at what frequency demyelinated motor neurons fail to propagate
action potentials. Knowing that patients with CIDP have abnormal motor unit firing rates
and overall neuromuscular block it would be important to know at what specific
frequency peripheral axons demonstrate this failure to provide verification for the
blockage in larger later recruited type II motor units.
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Furthermore, certain inferences made in Chapters 4 and 5 could have been further
supported or enhanced with the inclusion of skeletal muscle biopsies. The incorporation
of muscle biopsies could have supported the ideas in Chapter 3 of neuromuscular
remodeling (fiber type grouping) in patients with CIDP. Muscle biopsies could also give
a superior molecular understanding of muscle quality by evaluating single myofibril
morphology

20

. Nevertheless, the inclusion of muscle biopsies was not reasonable for

these experiments as the majority of studies contained within this thesis concentrated on
the dorsiflexor muscle groups, which are not considered suitable muscles to biopsy in
comparison to muscles of the thigh for example. Obtaining and analyzing biopsies
located in the quadriceps would provide insight for comparison with the TA, given the
length-dependent nature of CIDP and the different fiber type proportions of these
dissimilar muscle groups

21

. In combination with the procedures mentioned above, it

would be advantageous to include standard clinical measures of mobility or functional
capacity, such as balance and coordination tests. Moreover, subjective questionnaires
that assess physical activity could offer evidence regarding the physical status of the
subjects studied. The inclusion of these subjective measures may help delineate
consequences of CIDP on the neuromuscular system.
Finally, a longitudinal study of patients with CIDP, as well a more detailed outline of
patient’s treatment regime could provide greater insight into the progression of CIDP
related neuromuscular dysfunctions

20

. Concurrent assessments of the motor system and

the changes reflected by the different treatments (IVIG, PE and prednisone) offered to
patients with CIDP would be helpful in determining how this autoimmune neuropathy is
affected by differing treatment modalities or the protective effects treatments have on
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neuromuscular properties of patients with CIDP

22,23,24,25

. Conceivably, a longitudinal

study would also provide an opportunity to assess the effects of aging on CIDP.

6.4

Summary and Significance

Chronic Inflammatory Demyelinating Polyneuropathy causes numerous detrimental
physiological and functional alterations to the human neuromuscular system. This
dissertation comprises an amalgamated collection of novel and foundational experiments
in patients with CIDP. Firstly, it provides concrete evidence for the chronic loss of
demyelinated motor units that underlie muscle atrophy and weakness in patients with
CIDP (Chapter 2). Secondly, this body of work demonstrates that in addition to the loss
of motor units, patients with CIDP display severe instability in remaining motor units
(Chapter 2). Furthermore, for the first time experimentally, I illustrate that patients with
CIDP have abnormal motor unit firing rates across a broad range of contraction
intensities. Indeed, shown in this thesis the chronic loss of motor units, the detectable
instability and conduction block of action potentials seem to be associated with skeletal
muscle atrophy as well the intramuscular infiltration of non-contractile tissue (Chapters 4
and 5). Combined, the investigations contained within thesis provide a basis that will
direct future experiments to further elucidate mechanisms that aid in the understanding of
how CIDP influences the neuromuscular system.
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